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http://dx.doi.org/10.10and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. It also ex-
amines the impact of AD on women compared with men. An estimated 5.2 million Americans have
AD. Approximately 200,000 people younger than 65 years with AD comprise the younger onset AD
population; 5 million are age 65 years or older. By mid-century, fueled in large part by the baby boom
generation, the number of people living with AD in the United States is projected to grow by about 9
million. Today, someone in the country develops AD every 67 seconds. By 2050, one new case of AD
is expected to develop every 33 seconds, or nearly a million new cases per year, and the total esti-
mated prevalence is expected to be 13.8 million. In 2010, official death certificates recorded
83,494 deaths from AD, making AD the sixth leading cause of death in the United States and the fifth
leading cause of death in Americans aged 65 years or older. Between 2000 and 2010, the proportion of
deaths resulting from heart disease, stroke, and prostate cancer decreased 16%, 23%, and 8%, respec-
tively, whereas the proportion resulting from AD increased 68%. The actual number of deaths to
which AD contributes (or deaths with AD) is likely much larger than the number of deaths from
AD recorded on death certificates. In 2014, an estimated 700,000 older Americans will die with
AD, and many of them will die from complications caused by AD. In 2013, more than 15 million
family members and other unpaid caregivers provided an estimated 17.7 billion hours of care to peo-
plewith AD and other dementias, a contribution valued at more than $220 billion. Average per-person
Medicare payments for services to beneficiaries aged 65 years and older with AD and other dementias
are more than two and a half times as great as payments for all beneficiaries without these conditions,
and Medicaid payments are 19 times as great. Total payments in 2014 for health care, long-term care,
and hospice services for people aged 65 years and older with dementia are expected to be $214 bil-
lion. AD takes a stronger toll on women than men. More women than men develop the disease, and
women are more likely than men to be informal caregivers for someonewith AD or another dementia.
As caregiving responsibilities becomemore time consuming and burdensome or extend for prolonged
durations, women assume an even greater share of the caregiving burden. For every man who spends
21 to more than 60 hours per week as a caregiver, there are 2.1 women. For every man who lives with
the care recipient and provides around-the-clock care, there are 2.5 women. In addition, for every man
who has provided caregiving assistance for more than 5 years, there are 2.3 women.
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Open access under CC BY-NC-ND(AD), the most common type of dementia, as well as
other dementias. Background and context for interpretation
of the data are contained in the Overview. This information
includes definitions of the various types of dementia
and a summary of current knowledge about AD. Additional
sections address prevalence, mortality and morbidity,
caregiving, and use and costs of care and services.
The Special Report discusses women and Alzheimer’s dis-
ease. license.
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Facts and Figures includes:
 Proposed criteria and guidelines for diagnosing AD
from the National Institute on Aging (NIA) and the
Alzheimer’s Association.
 Overall number of Americans with AD nationally and
for each state.
 Proportion of women and men with AD and other de-
mentias.
 Estimates of lifetime risk for developing AD.
 Number of deaths due to AD nationally and for each
state, and death rates by age.
 Number of family caregivers, hours of care provided,
economic value of unpaid care nationally and for
each state, and the impact of caregiving on caregivers.
 Use and costs of health care, long-term care, and hos-
pice care for people with AD and other dementias.
 The burden of Alzheimer’s disease on women com-
pared with men.
The Appendices detail sources and methods used to
derive data in this report.
This report frequently cites statistics that apply to individ-
ualswith all types of dementia.When possible, specific infor-
mation about AD is provided; in other cases, the reference
may be a more general one of “AD and other dementias.”2. Overview of AD
AD is the most common type of dementia. Dementia is an
overall term for diseases and conditions characterized by a
decline in memory or other thinking skills that affects a per-
son’s ability to perform everyday activities. Dementia is
caused by damage to nerve cells in the brain, which are
called neurons. As a result of the damage, neurons can no
longer function normally and may die. This, in turn, can
lead to changes in one’s memory, behavior, and ability to
think clearly. In AD, the damage to and death of neurons
eventually impair one’s ability to carry out basic bodily func-
tions such as walking and swallowing. People in the final
stages of the disease are bedbound and require around-the-
clock care. AD is ultimately fatal.2.1. Dementia2.1.1. Definition and diagnosis
Physicians often define dementia based on the criteria
given in the Diagnostic and Statistical Manual of Mental
Disorders (DSM). In 2013, the American Psychiatric Asso-
ciation released the fifth edition of theDSM (DSM-5), which
incorporates dementia into the diagnostic categories of ma-
jor and mild neurocognitive disorders [1].
To meet DSM-5 criteria for major neurocognitive disor-
der, an individual must have evidence of significant cogni-
tive decline (e.g., decline in memory, language, orlearning), and the cognitive decline must interfere with inde-
pendence in everyday activities (e.g., assistance may be
needed with complex activities such as paying bills or man-
aging medications).
To meetDSM-5 criteria for mild neurocognitive disorder,
an individual must have evidence of modest cognitive de-
cline, but the decline does not interfere with everyday activ-
ities. (Individuals can still perform complex activities such
as paying bills or managing medications, but the activities
require greater effort.)
For both major and mild neurocognitive disorders, DSM-
5 instructs physicians to specify whether the condition is due
to AD, frontotemporal lobar degeneration, Lewy body dis-
ease, or a variety of other conditions.
2.1.2. Types of dementia
When an individual has symptoms of dementia, a physi-
cian must conduct tests to identify the underlying brain dis-
ease or other condition that is causing symptoms. Different
types of dementia are associated with distinct symptom pat-
terns and brain abnormalities, as described in Table 1.
Increasing evidence from long-term observational and
autopsy studies indicates that many people with dementia,
especially those in the older age groups, have brain abnor-
malities associated with more than one type of dementia
[2–6]. This is called mixed dementia.
Some conditions result in symptoms that mimic dementia
but that, unlike dementia, may be reversed with treatment.
An analysis of 39 articles describing 5620 people with
dementia-like symptoms reported that 9% had symptoms
that were mimicking dementia and potentially reversible
[7]. Common causes of these symptoms are depression,
delirium, side effects from medications, thyroid problems,
certain vitamin deficiencies, and excessive use of alcohol.
In contrast, AD and other dementias cannot be reversed
with current treatments.2.2. Alzheimer’s disease
AD was first identified more than 100 years ago, but re-
search into its symptoms, causes, risk factors, and treatment
has gained momentum only in the last 30 years. Although re-
search has revealed a great deal about AD, much is yet to be
discovered about the precise biologic changes that cause
AD, why it progresses at different rates among affected indi-
viduals, and how the disease can be prevented, slowed, or
stopped.
2.2.1. Symptoms
AD affects people in different ways. The most common
initial symptom is a gradually worsening ability to remem-
ber new information. This occurs because the first neurons
to malfunction and die are usually neurons in brain regions
involved in forming new memories. As neurons in other
parts of the brain malfunction and die, individuals
Table 1
Types of dementia and their typical characteristics*
Type of dementia Characteristics
AD Most common type of dementia; accounts for an estimated 60% to 80% of cases. About half of these cases involve solely Alzheimer’s
pathology; many have evidence of pathologic changes related to other dementias. This is called mixed dementia (see mixed dementia in
this table).
Difficulty remembering recent conversations, names, or events is often an early clinical symptom; apathy and depression are also often
early symptoms. Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavior changes and,
ultimately, difficulty speaking, swallowing, and walking.
Revised criteria and guidelines for diagnosingADwere proposed and published in 2011. They recommend that AD be considered a slowly
progressive brain disease that begins well before clinical symptoms emerge.
The hallmark pathologies of AD are the progressive accumulation of the protein fragment b-amyloid (plaques) outside neurons in the
brain and twisted strands of the protein tau (tangles) inside neurons. These changes are eventually accompanied by the damage and
death of neurons.
Vascular dementia Previously known as multi-infarct or poststroke dementia, vascular dementia is less common as a sole cause of dementia than AD,
accounting for about 10% of dementia cases. However, it is very common in older individuals with dementia, with about 50% having
pathologic evidence of vascular dementia (infarcts). In most cases, the infarcts coexist with AD pathology [8].
Impaired judgment or the ability to make decisions, plan, or organize is more likely to be the initial symptom, as opposed to the memory
loss often associated with the initial symptoms of AD.
Vascular dementia occurs most commonly from blood vessel blockage or damage leading to infarcts (strokes) or bleeding in the brain. The
location, number, and size of the brain injuries determine whether dementia will result and how the individual’s thinking and physical
functioning will be affected.
In the past, evidence of vascular dementia was used to exclude a diagnosis of AD (and vice versa). That practice is no longer considered
consistent with the pathologic evidence, which shows that the brain changes of both types of dementia commonly coexist. When two or
more types of dementia are present at the same time, the individual is considered to have mixed dementia (see mixed dementia in this
table).
DLB People with DLB have some of the symptoms common in AD but are more likely to have initial or early symptoms of sleep disturbances,
well-formed visual hallucinations and slowness, gait imbalance, or other parkinsonian movement features. These features, as well as
early visuospatial impairment, may occur in the absence of significant memory impairment.
Lewy bodies are abnormal aggregations (or clumps) of the protein a-synuclein that accumulates in neurons.When they develop in a part of
the brain called the cortex, dementia can result. a-Synuclein also aggregates in the brains of peoplewith PD, in which it is accompanied
by severe neuronal loss in a part of the brain called the substantia nigra. Although people with DLB and PD both have Lewy bodies, the
onset of the disease is marked by motor impairment in PD and cognitive impairment in DLB.
The brain changes of DLB alone can cause dementia. But very commonly, brains with DLB have coexisting AD pathology. In people with
both DLB and AD pathology, symptoms of both diseases may emerge and lead to some confusion in diagnosis. Vascular dementia can
also coexist and contribute to the dementia. When evidence of more than one dementia is present, the individual is said to have mixed
dementia (see mixed dementia in this table).
FTLD Includes dementias such as behavioral-variant FTLD, primary progressive aphasia, Pick’s disease, corticobasal degeneration, and
progressive supranuclear palsy.
Typical early symptoms include marked changes in personality and behavior and difficulty with producing or comprehending language.
Unlike AD, memory is typically spared in the early stages of disease.
Nerve cells in the front (frontal lobe) and side regions (temporal lobes) of the brain are especially affected, and these regions become
markedly atrophied (shrunken). In addition, the upper layers of the cortex typically become soft and spongy and have protein inclusions
(usually tau protein or the transactive response DNA-binding protein).
The brain changes of behavioral-variant FTLDmay occur in those aged 65 years and older, similar to AD, but most people with this form
of dementia develop symptoms at a younger age (at about age 60 years). In this younger age group, FTLD is the second most common
degenerative dementia.
Mixed dementia Characterized by the hallmark abnormalities of more than one type of dementia—most commonly AD combined with vascular dementia,
followed by AD with DLB, and AD with vascular dementia and DLB. Vascular dementia with DLB is much less common [3,4].
Recent studies suggest that mixed dementia is more common than previously recognized, with about half of those with dementia having
mixed pathologies [3,4].
PD dementia Problems with movement (slowness, rigidity, tremor, and changes in gait) are common symptoms of PD.
In PD, a-synuclein aggregates appear in an area deep in the brain called the substantia nigra. The aggregates are thought to cause
degeneration of the nerve cells that produce dopamine.
The incidence of PD is about one-tenth that of AD. As PD progresses, it often results in dementia secondary to the accumulation of Lewy
bodies in the cortex (similar to DLB) or the accumulation of b-amyloid clumps and tau tangles (similar to AD).
Creutzfeldt-Jakob
disease
This very rare and rapidly fatal disorder impairs memory and coordination and causes behavior changes.
Results from a misfolded protein (prion) that causes other proteins throughout the brain to misfold and malfunction.
May be hereditary (caused by a gene that runs in one’s family), sporadic (unknown cause) or caused by a known prion infection.
A specific form called variant Creutzfeldt-Jakob disease is believed to be caused by consumption of products from cattle affected by mad
cow disease.
(Continued )
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Table 1
Types of dementia and their typical characteristics* (Continued )
Type of dementia Characteristics
Normal pressure
hydrocephalus
Symptoms include difficulty walking, memory loss, and inability to control urination.
Caused by impaired reabsorption of cerebrospinal fluid and the consequent buildup of fluid in the brain, increasing pressure in the brain.
People with a history of brain hemorrhage (particularly subarachnoid hemorrhage) and meningitis are at increased risk.
Can sometimes be corrected with surgical installation of a shunt in the brain to drain excess fluid.
Abbreviations: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; PD, Parkinson’s disease; FTLD, frontotemporal lobar degeneration.
*For more information on these and other types of dementia, visit www.alz.org.
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symptoms of AD:
 Memory loss that disrupts daily life.
 Challenges in planning or solving problems.
 Difficulty completing familiar tasks at home, at work,
or at leisure.
 Confusion with time or place.
 Trouble understanding visual images and spatial rela-
tionships.
 New problems with words in speaking or writing.
 Misplacing things and losing the ability to retrace
steps.
 Decreased or poor judgment.
 Withdrawal from work or social activities.
 Changes in mood and personality, including apathy
and depression.
For more information about symptoms of AD, visit www.
alz.org/10signs.
Individuals progress through AD at different rates. As they
pass through different stages of the disease, individuals’ cog-
nitive and functional abilities decline. In the final, advanced
stage of the disease, people need help with basic activities
of daily living (ADLs) such as bathing, dressing, eating, and
using the bathroom; lose their ability to communicate; fail
to recognize loved ones; and become bedbound and reliant
on around-the-clock care. When individuals have difficulty
moving, they are more vulnerable to infections, including
pneumonia (infection of the lungs). AD-related pneumonia
is often a contributing factor to the death of people with AD.2.2.2. Changes in the brain that are associated with AD
A healthy adult brain has about 100 billion neurons, each
with long, branching extensions. These extensions enable in-
dividual neurons to form connections with other neurons. At
such connections, called synapses, information flows in tiny
bursts of chemicals that are released by one neuron and de-
tected by a receiving neuron. The brain contains about 100
trillion synapses. They allow signals to travel rapidly through
the brain’s circuits, creating the cellular basis of memories,
thoughts, sensations, emotions, movements, and skills. AD in-
terferes with the proper functioning of neurons and synapses.
Among the brain changes believed to contribute to the de-
velopment of AD are the accumulation of the protein b-amy-loid outside neurons (called b-amyloid plaques) and the
accumulation of an abnormal form of the protein tau inside
neurons (called tau tangles). In AD, information transfer at
synapses begins to fail, the number of synapses declines,
and neurons eventually die. The accumulation of b-amyloid
is believed to interfere with the neuron-to-neuron communi-
cation at synapses and to contribute to cell death. Tau tangles
block the transport of nutrients and other essential molecules
in the neuron and are also believed to contribute to cell death.
The brains of people with advanced AD show dramatic
shrinkage from cell loss and widespread debris from dead
and dying neurons.
The brain changes of AD may begin 20 or more years
[9–11] before symptoms appear. The time between the initial
brain changes of AD and the symptoms of advanced AD is
considered by scientists to represent the “continuum” of AD.
At the start of the continuum, the individual is able to
function normally despite these brain changes. Further along
the continuum, the brain can no longer compensate for the
neuronal damage that has occurred, and the individual shows
subtle decline in cognitive function. Later, the damage to
and death of neurons is so significant that the individual
shows obvious cognitive decline, including symptoms such
as memory loss or confusion as to time or place. Later still,
basic bodily functions such as swallowing are impaired.
2.2.3. Genetic mutations that cause AD
A small percentage of AD cases, an estimated 1% or less
[12], develop as a result of mutations in any of three genes.
A genetic mutation is an abnormal change in the sequence
of chemical pairs that make up genes. These mutations
involve the gene for the amyloid precursor protein and the
genes for the presenilin 1 and 2 proteins. Inheriting any of
these genetic mutations guarantees that an individual will
develop AD. In such individuals, disease symptoms tend to
develop before the age of 65 years, sometimes as early as
age 30 years, whereas the vast majority of individuals with
AD have late-onset disease, occurring at age 65 years or later.
2.2.4. Risk factors for AD
With the exception of the rare cases of AD caused by
known genetic mutations, experts believe that AD, like other
common chronic diseases, develops as a result of multiple
factors rather than a single cause. Following are known
risk factors for AD.
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The greatest risk factor for AD is advanced age. Most
people with AD are diagnosed at age 65 years or older. Peo-
ple younger than 65 years can also develop the disease,
although this is much rarer. (See the Prevalence section.)
While age is the greatest risk factor, AD is not a normal
part of aging, and advanced age alone is not sufficient to
cause the disease.
2.2.4.2. Family history
Individuals who have a parent, brother, or sister with AD
are more likely to develop the disease than those who do not
have a first-degree relative with AD [13–15]. Those who
have more than one first-degree relative with AD are at
even higher risk [16]. When diseases run in families,
heredity (genetics), shared environmental and lifestyle
factors, or both may play a role. The increased risk
associated with having a family history of AD is not
entirely explained by whether the individual has inherited
the apolipoprotein E (APOE) 34 risk gene.
2.2.4.3. APOE 34 gene
The APOE gene provides the blueprint for a protein that
carries cholesterol in the bloodstream. Everyone inherits one
form of the APOE gene—32, 33, or 34—from each parent.
The 33 form is the most common [17], with about 60% of
the US population inheriting 33 from both parents [18].
The 32 and 34 forms are much less common. An estimated
20% to 30% of individuals in the United States have one
or two copies of the 34 form [17,18]; approximately 2% of
the US population has two copies of 34 [18]. The
remaining 10% to 20% have one or two copies of 32.
Having the 33 form is believed to neither increase nor de-
crease one’s risk of AD, whereas having the 32 form may de-
crease one’s risk. The 34 form, however, increases the risk of
developing AD and of developing it at a younger age. Those
who inherit two 34 genes have an even higher risk. Research-
ers estimate that between 40% and 65% of people diagnosed
with AD have one or two copies of the APOE 34 gene
[17,19,20].
Unlike inheriting a known genetic mutation that causes
AD, inheriting the 34 form of the APOE gene does not guar-
antee that an individual will develop AD. This is also true for
several genes that appear to increase the risk of AD but that
have a limited overall effect in the population because they
are rare or only slightly increase risk.
2.2.4.4. Mild cognitive impairment
Mild cognitive impairment (MCI) is a condition in which
an individual has mild but measurable changes in thinking
abilities that are noticeable to the person affected and to fam-
ily members and friends but that do not affect the individu-
al’s ability to carry out everyday activities. People withMCI,
especiallyMCI involving memory problems, are more likely
to develop AD and other dementias than people without
MCI. However, MCI does not always lead to dementia.
For some individuals, MCI reverts to normal cognition onits own or remains stable. In other cases, such as when a
medication causes cognitive impairment, MCI is mistakenly
diagnosed. Therefore, it is important that people experienc-
ing cognitive impairment seek help as soon as possible for
diagnosis and possible treatment.
The proposed criteria and guidelines for diagnosis of AD
published in 2011 [21–24] suggest that in some cases, MCI
is actually an early stage of AD or another dementia.
2.2.4.5. Cardiovascular disease risk factors
Growing evidence suggests that the health of the brain is
closely linked to the overall health of the heart and blood
vessels. The brain is nourished by one of the body’s richest
networks of blood vessels. A healthy heart helps ensure that
enough blood is pumped through these blood vessels, and
healthy blood vessels help ensure that the brain is supplied
with the oxygen- and nutrient-rich blood it needs to function
normally.
Many factors that increase the risk of cardiovascular
disease are also associated with a higher risk of developing
AD and other dementias. These factors include smoking
[25–27], obesity (especially in midlife) [28–34], diabetes
[27,35–39], high cholesterol in midlife [30,40], and
hypertension in midlife [30,33,41–43].
Conversely, factors that protect the heart may also protect
the brain and reduce the risk of developing AD and other de-
mentias. Physical activity [37,44–46] appears to be one of
these factors. In addition, emerging evidence suggests that
consuming a diet that benefits the heart, such as one that is
low in saturated fats and rich in vegetables and vegetable-
based oils, may be associated with reduced AD and dementia
risk [37].
Unlike genetic risk factors, many of these cardiovascular
disease risk factors are modifiable—that is, they can be
changed to decrease the likelihood of developing cardiovas-
cular disease and, possibly, AD and other forms of dementia.
2.2.4.6. Social and cognitive engagement
Additional studies suggest that other modifiable risk
factors such as remaining mentally and socially active may
support brain health and possibly reduce the risk of AD
and other dementias [47–59]. Remaining socially and
cognitively active may help build cognitive reserve (see
Education), but the exact mechanism by which this may
occur is unknown. More research is needed to better
understand how social and cognitive engagement may
affect biological processes to reduce risk.
2.2.4.7. Education
People with fewer years of formal education are at higher
risk for AD and other dementias than those with more years
of formal education [60–64]. Some researchers believe that
having more years of education builds a “cognitive
reserve” that enables individuals to better compensate for
changes in the brain that could result in symptoms of AD
or another dementia [63,65–67]. According to the
cognitive reserve hypothesis, having more years of
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brain and enables the brain to compensate for the early brain
changes of AD by using alternate routes of neuron-to-neuron
communication to complete a cognitive task. However, some
scientists believe that the increased risk of dementia among
those with lower educational attainment may be explained
by other factors common to people in lower socioeconomic
groups such as increased risk for disease in general and less
access to medical care [68].
2.2.4.8. Traumatic brain injury
Moderate and severe traumatic brain injuries (TBIs) in-
crease the risk of developing AD and other dementias [69].
TBI is the disruption of normal brain function caused by a
blow or jolt to the head or penetration of the skull by a
foreign object. Not all blows or jolts to the head disrupt
brain function. Moderate TBI is defined as a head injury
resulting in loss of consciousness or posttraumatic amnesia
that lasts more than 30 minutes. If loss of consciousness or
posttraumatic amnesia lasts more than 24 hours, the injury
is considered severe. Half of all moderate and severe TBIs
are caused by motor vehicle accidents [70]. Moderate TBI
is associated with twice the risk of developing AD and
other dementias compared with no head injuries, and
severe TBI is associated with 4.5 times the risk [71].
Groups that experience repeated head injuries such as
boxers, football players, and combat veterans are at higher
risk of dementia, cognitive impairment, and neurodegenera-
tive disease than individuals who experience no head injury
[72–78]. Evidence suggests that even repeated mild TBI
might promote neurodegenerative disease [79–81]. Some
of these neurodegenerative diseases, such as chronic
traumatic encephalopathy, can only be distinguished from
AD on autopsy.
2.2.5. Diagnosis
A diagnosis of AD is most commonlymade by an individ-
ual’s primary care physician. The physician obtains a medi-
cal and family history, including psychiatric history and
history of cognitive and behavioral changes. The physician
also asks a family member or other person close to the indi-
vidual to provide input. In addition, the physician conducts
cognitive tests and physical and neurologic examinations
and may request that the individual undergo magnetic reso-
nance imaging scans. Magnetic resonance imaging scans
can help identify brain changes such as the presence of a tu-
mor or evidence of a stroke that could explain the individu-
al’s symptoms.
2.2.6. A modern diagnosis of AD: Proposed criteria and
guidelines
In 2011, the NIA and the Alzheimer’s Association pro-
posed revised criteria and guidelines for diagnosing AD
[21–24]. These criteria and guidelines updated diagnostic
criteria and guidelines published in 1984 by the
Alzheimer’s Association and the National Institute ofNeurological Disorders and Stroke [82]. In 2012, the NIA
and the Alzheimer’s Association also proposed new
guidelines to help pathologists describe and categorize the
brain changes associated with AD and other dementias [83].
It is important to note that more research is needed before
the proposed diagnostic criteria and guidelines can be used
in clinical settings such as in a doctor’s office.
2.2.6.1. Differences between the original and proposed
criteria
The 1984 diagnostic criteria and guidelines were based
chiefly on a doctor’s clinical judgment about the cause of
an individual’s symptoms, taking into account reports from
the individual, family members, and friends; results of cog-
nitive tests; and general neurologic assessment. The new cri-
teria and guidelines incorporate two notable changes:
(1) They identify three stages of AD, with the first occur-
ring before symptoms such as memory loss develop.
In contrast, for AD to be diagnosed using the 1984
criteria, memory loss and a decline in thinking abil-
ities must have already occurred.
(2) They incorporate biomarker tests. A biomarker is a
biological factor that can be measured to indicate
the presence or absence of disease or the risk of de-
veloping a disease. For example, blood glucose level
is a biomarker of diabetes and cholesterol level is a
biomarker of heart disease risk. Levels of certain pro-
teins in fluid (e.g., levels of b-amyloid and tau in the
cerebrospinal fluid and blood) are among several fac-
tors being studied as possible biomarkers for AD.
2.2.6.2. The three stages of AD proposed by the 2011
criteria and guidelines
The three stages of AD proposed by the 2011 criteria and
guidelines are preclinical AD,MCI due to AD, and dementia
due to AD. An individual who does not yet have outward
symptoms of AD but does have some of the early brain
changes of AD (as detected by brain imaging and other bio-
marker tests) would be said to have preclinical AD. Those
who have very mild symptoms but can still perform every-
day tasks would be described as having MCI due to AD. In-
dividuals whose symptoms are more pronounced and
interfere with carrying out everyday tasks would be said to
have dementia due to AD.
2.2.6.2.1. Preclinical AD
In this stage, individuals have measurable changes in
the brain, cerebrospinal fluid, and/or blood (biomarkers)
that indicate the earliest signs of disease, but they have
not yet developed noticeable symptoms such as memory
loss. This preclinical or presymptomatic stage reflects
current thinking that AD-related brain changes may begin
20 years or more before symptoms occur [9–11].
Although the 2011 criteria and guidelines identify
preclinical disease as a stage of AD, they do not
establish diagnostic criteria that doctors can use now.
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2.2.6.2.2. MCI due to AD
Individuals with MCI have mild but measurable changes
in thinking abilities that are noticeable to the person affected
and to family members and friends but that do not affect the
individual’s ability to carry out everyday activities. Studies
indicate that as many as 10% to 20% of people aged 65 years
or older have MCI [84–86]. Among people whose MCI
symptoms cause them enough concern to contact their
physicians for an examination, as many as 15% progress
from MCI to dementia each year. Nearly half of all people
who have visited a doctor about MCI symptoms will
develop dementia in 3 or 4 years [87].
When MCI is identified through community sampling, in
which individuals in a community who meet certain criteria
are assessed regardless of whether they have memory or cog-
nitive complaints, the estimated percentage of people who
will progress to AD is slightly lower—up to 10% per year
[88]. Further cognitive decline is more likely among
individuals whose MCI involves memory problems than
among those whose MCI does not involve memory
problems. Over 1 year, most individuals with MCI who are
identified through community sampling remain cognitively
stable. Some, primarily those without memory problems,
experience an improvement in cognition or revert to normal
cognitive status [89]. It is unclear why some people with
MCI develop dementia and others do not. When an
individual with MCI goes on to develop dementia, many
scientists believe the MCI is actually an early stage of the
particular form of dementia, rather than a separate condition.
After accurate and reliable biomarker tests for AD have
been identified, the 2011 criteria and guidelines recommend
biomarker testing for people with MCI to learn whether they
have biological changes that put them at high risk of devel-
oping AD and other dementias. If testing shows that changes
in the brain, cerebrospinal fluid, and/or blood are similar to
the changes of AD, the proposed criteria and guidelines rec-
ommend a diagnosis of MCI due to AD. However, this diag-
nosis cannot currently be made, as additional research is
needed to validate the 2011 criteria before they can be
used in clinical settings.
2.2.6.2.3. Dementia due to AD
This stage, as described by the 2011 diagnostic criteria
and guidelines, is characterized by quite noticeable memory,
thinking, and behavioral symptoms that, unlike MCI, impair
a person’s ability to function in daily life.
2.2.6.3. Biomarker tests
The 2011 criteria and guidelines identify two biomarker
categories: (1) biomarkers showing the level of b-amyloid
accumulation in the brain and (2) biomarkers showing that
neurons in the brain are injured or actually degenerating.
Many researchers believe that future treatments to slow or
stop the progression of AD and preserve brain function(called “disease-modifying” treatments) will be most effec-
tivewhen administered during the preclinical andMCI stages
of the disease. Biomarker tests will be essential to identify
which individuals are in these early stages and should receive
disease-modifying treatment. They also will be critical for
monitoring the effects of treatment. At this time, however,
more research is needed to validate the accuracy of bio-
markers and better understand which biomarker test or com-
bination of tests ismost effective in diagnosingAD. Themost
effective test or combination of tests may differ depending on
the stage of the disease and the type of dementia [90].
2.2.6.4. Progress toward implementing criteria and
validating biomarkers
Since the revised criteria were published in 2011, dozens
of scientists have published results of studies implementing
the revised criteria in research settings, examining the accu-
racy of biomarker tests in detecting and predicting AD, and
using biomarker tests to distinguish AD from other forms of
dementia. Although additional studies are needed before the
revised criteria and guidelines are ready for use in physi-
cians’ offices, preliminary evidence supporting the revised
criteria and biomarker tests is growing [91–107].
2.2.7. Treatment of AD
2.2.7.1. Pharmacologic treatment
Pharmacologic treatments are treatments in which medi-
cation is administered to slow or stop an illness or treat its
symptoms. None of the treatments available today for AD
slows or stops the malfunction and death of neurons in the
brain that cause AD symptoms and eventually make the dis-
ease fatal. However, dozens of drugs and therapies aimed at
slowing or stopping neuronal malfunction and death are
being studied by scientists around the world. Five drugs
have been approved by the US Food and Drug Administra-
tion that temporarily improve symptoms of AD by increas-
ing the amount of chemicals called neurotransmitters in
the brain. The effectiveness of these drugs varies from per-
son to person.
Despite the lack of disease-modifying therapies, studies
have consistently shown that active management of AD
and other dementias can improve quality of life through all
stages of the disease for individuals with dementia and their
caregivers [108–110]. Active management includes
(1) appropriate use of available treatment options,
(2) effective management of coexisting conditions,
(3) coordination of care among physicians, other health-
care professionals, and lay caregivers, (4) participation in ac-
tivities and/or adult day care programs, and (5) taking part in
support groups and supportive services.
2.2.7.2. Nonpharmacologic therapy
Nonpharmacologic therapies are those that use ap-
proaches other than medication such as physical therapy
and reminiscence therapy (therapy in which photos and other
familiar items may be used to elicit recall). As with
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not been shown to alter the course of AD. Rather than alter-
ing the disease course, nonpharmacologic therapies are often
used with the goal of maintaining cognitive function or help-
ing the brain compensate for impairments. Nonpharmaco-
logic therapies are also used with the goals of improving
quality of life or reducing behavioral symptoms such as de-
pression, apathy, wandering, sleep disturbances, agitation,
and aggression.
Awide range of nonpharmacologic interventions have been
proposed or studied. The Cochrane Database of Systematic
Reviews of published articles on nonpharmacologic therapies
found that few have sufficient evidence supporting their effec-
tiveness [111]. Of the 25 categories of nonpharmacologic
therapies reviewed in the Cochrane Database, only cognitive
stimulation had findings that suggested a beneficial effect. A
different systematic review found that there were too few
high-quality studies to show that nonpharmacologic therapy
for dementia was effective. However, of the high-quality stud-
ies reviewed, cognitive training, cognitive stimulation, and
training in ADLs appeared most successful in reaching the
aims of the interventions [112]. A meta-analysis, which com-
bines results from many studies, found the most successful
nonpharmacologic interventions for neuropsychiatric symp-
toms of dementia were multicomponent, tailored to the needs
of the caregiver and person with dementia, and delivered at
home with periodic follow-up [113].3. Prevalence
Millions of Americans have AD and other dementias. The
number of Americans with AD and other dementias will
grow each year as the size and proportion of the US popula-
tion aged 65 years and older continue to increase. The num-
ber will escalate rapidly in coming years as the baby boom
generation ages.
Estimates from selected studies on the prevalence and
characteristics of people with AD and other dementiasFig. 1. Proportion of people with AD in the United States by age. Percen-
tages may not total 100 because of rounding. Created from data from Hebert
et al. [114].A3vary depending on how each study was conducted. Data
from several studies are used in this section.
3.1. Prevalence of AD and other dementias
The prevalence of AD refers to the proportion of people in
a population who have AD at a given point in time. People
who have AD at a given time are said to have prevalent dis-
ease. Prevalence and the number of prevalent cases describe
the magnitude of the burden of AD on the community and
the health-care system, but it does not provide an estimate
of the risk of developing the disease. An estimated 5.2 mil-
lion Americans of all ages have AD in 2014. This includes an
estimated 5 million people aged 65 years and older [114]A1
and approximately 200,000 individuals younger than 65
years who have younger onset AD [115].
 One in nine people aged 65 years and older (11%) has
AD.A2
 About one-third of people aged 85 years and older
(32%) have AD [114].
 Of those with AD, the vast majority (82%) are age 75
years or older (Fig. 1) [114].A3
The estimated prevalence of AD for people aged 65
years and older comes from a recent study using the latest
data from the 2010 US Census and the Chicago Health
and Aging Project (CHAP), a population-based study of
chronic health diseases of older people [114].
National estimates of the prevalence of all forms of de-
mentia are not available from CHAP but are available
from other population-based studies, including the Aging,
Demographics, and Memory Study (ADAMS), a nationally
representative sample of older adults [116,117].A4 Based
on estimates from ADAMS, 13.9% of people aged 71
years and older in the United States have dementia [116].
Prevalence studies such as CHAP and ADAMS are de-
signed so that all individuals with dementia are detected.
But in the community, only about half of those who would
meet the diagnostic criteria for AD and other dementias
have received a diagnosis of dementia from a physician
[118]. Because AD is underdiagnosed, half of the estimated
5.2 million Americans with AD may not know they have it.
3.1.1. Preclinical AD
The estimates fromCHAP andADAMS are based on com-
monly accepted criteria for diagnosing AD that have been
used since 1984. These criteria are applicable only after the
onset of symptoms. But as described in the Overview, revised
criteria and guidelines by the Alzheimer’s Association and
NIA were published in 2011 [21–24] proposing that AD
begins before the onset of symptoms. The 2011 criteria
identify three stages of AD: preclinical AD, MCI due to
AD, and dementia due to AD. Because more research is
needed to validate the accuracy of biomarker tests in
detecting preclinical AD and MCI due to AD, the number of
people in these stages is difficult to estimate. However, if
AD could be detected before symptoms developed, the
Fig. 2. Proportion of people aged 65 years or older with AD and other dementias. The Hispanic group for this study was primarily Caribbean-American. Created
from unpublished data from Gurland et al. [133].
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clinical) would be much larger than what is presented in this
report.
3.1.2. Subjective cognitive decline
The experience of worsening or more frequent confusion
or memory loss (often referred to as subjective cognitive de-
cline) can be one of the earliest warning signs of AD. Be-
cause of this, researchers have recently begun to study
subjective cognitive decline as a way to identify people
who are at high risk of developing AD and other dementias
[119,120], as well as MCI. Subjective cognitive decline does
not refer to occasionally forgetting your keys or the name of
someone you recently met; it refers to more serious issues
such as having trouble remembering how to do things you
have always done or forgetting things that you would
normally know. Not all those who experience subjective
cognitive decline go on to develop MCI or AD and other
dementias, but many do [121]. In 2011, 22 states added
questions on self-perceived confusion and memory loss to
their Behavioral Risk Factor Surveillance System (BRFSS)
surveys, which are developed in coordination with the Cen-
ters for Disease Control and Prevention (CDC). Data from
21 of the states showed that 12.7% of Americans aged 60
years and older reported experiencing worsening confusion
or memory loss, but 81% of them had not consulted a
health-care professional [122]. Individuals experiencing
serious declines in memory and other cognitive abilities
should consult a health-care professional about these issues.
3.1.3. Prevalence of AD and other dementias in women and
men
More women than men have AD and other dementias.
Almost two-thirds of Americans with AD are women
[114].A5 Of the 5 million people aged 65 years and olderwith AD in the United States, 3.2 million are women and
1.8 million are men [114].A5 Based on estimates from
ADAMS, among people aged 71 years and older, 16% of
women have AD and other dementias compared with
11% of men [116,123].
The observation that more women than men have AD
and other dementias is primarily explained by the fact
that women live longer, on average, than men, and older
age is the greatest risk factor for AD [123,124]. Many
studies of the age-specific incidence (development of new
cases) of AD [61,62,124–128] or any dementia
[60,61,125,126,129] have found no significant difference
between the percentages of men and women who develop
AD or other dementias. Thus, there is no evidence that
women are more likely than men to develop dementia at
any given age.
3.1.4. Prevalence of AD and other dementias by years of
education
People with fewer years of education appear to be at
higher risk for AD and other dementias than those with
more years of education [60–64]. Some of the possible
reasons are explained in the Risk Factors for AD section
of the Overview.
3.1.5. Prevalence of AD and other dementias in older
whites, African-Americans, and Hispanics
Although there are more non-Hispanic whites living with
AD and other dementias than any other racial or ethnic group
in the United States, older African-Americans and Hispanics
are more likely than older whites to have AD and other de-
mentias [130,131]. A review of many studies by an expert
panel concluded that older African-Americans are about
twice as likely to have AD and other dementias as older
whites [132], and Hispanics are about 1.5 times as likely
Fig. 3. Estimated lifetime risks for AD, by age and sex, from the Framingham Study. Created from data from Seshadri et al. [142].
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Fig. 2 shows the estimated prevalence for each group, by
age, according to one large study. (Note: the Hispanic
group for this study was primarily Caribbean-American,
whereas most Hispanics in the United States are Mexican-
American. The prevalence in Caribbean-Americans may
be more similar to that in African-Americans, contributing
to the higher observed prevalence for Hispanics in this study
than estimated by the expert panel.)
Despite some evidence of racial differences in the influ-
ence of genetic risk factors on AD and other dementias
[134], genetic factors do not appear to account for the
large prevalence differences among racial groups
[135,136]. Instead, health conditions such as high blood
pressure and diabetes that may increase one’s risk for AD
or another dementia are believed to account for these
differences because they are more prevalent in African-
American and Hispanic people. Lower levels of education
and other socioeconomic characteristics in these commun-
ities may also increase risk. Some studies suggest that differ-
ences based on race and ethnicity do not persist in detailed
analyses that account for these factors [61,116].
There is evidence thatmissed diagnoses aremore common
among older African-Americans and Hispanics than among
older whites [137,138], but it is unclear whether disparities
in missed diagnoses have lessened in recent years. Recent
data for Medicare beneficiaries found that AD or another
dementia had been diagnosed in 8.2% of white
beneficiaries, 11.3% of African-American beneficiaries, and
12.3% of Hispanic beneficiaries [139]. Although rates of
diagnosiswere higher amongAfrican-Americans than among
whites, this difference was not as great as would be expected
(twice the percentage ofwhites) based on the estimated differ-
ences found in prevalence studies (Fig. 2), which are designed
to detect all people who have dementia.3.2. Incidence of AD
While prevalence is the number of existing cases of a dis-
ease in a population at a given time, incidence is the number
of new cases of a disease that develop in a given period of
time in a defined population—in this case, the United States
population aged 65 years or older. Approximately 469,000
people aged 65 years or older will develop AD in the United
States in 2014.A7 The number of new cases of AD increases
dramatically with age: in 2014, there will be approximately
59,000 new cases among people aged 65 to 74 years,
172,000 new cases among people aged 75 to 84 years, and
238,000 new cases among people aged 85 years and older
(the “oldest old”) [140].A7 Although some studies have
reported that incidence rates do not continue to rise after
age 90 years, at least one large study indicates that
previous observations of a leveling off of incidence among
the oldest old may be due to sparse data for this group
[141]. Because of the increasing number of people aged 65
years and older in the United States, particularly the oldest
old, the annual number of new cases of AD and other
dementias is projected to double by 2050 [140].
 Every 67 seconds, someone in the United States devel-
ops AD.A8
 By mid-century, someone in the United States will de-
velop the disease every 33 seconds.A83.3. Lifetime risk of AD
Lifetime risk is the probability that someone of a given
age will develop a condition during their remaining life
span. Data from the Framingham Study were used to es-
timate lifetime risks of AD and any dementia [142].A9
The study found that 65-year-old women without demen-
tia had a 20% chance of developing dementia during the
Table 2
Projections of total numbers of Americans aged 65 years and older with
Alzheimer’s disease by state
State
Projected
Number w/
Alzheimer’s
(in thousands) 2014
Projected Number
w/Alzheimer’s
(in thousands) 2025
Percentage
Change
2014-2025
Alabama 86.0 110.0 27.9
Alaska 6.1 11.0 80.3
Arizona 120.0 200.0 66.7
Arkansas 52.0 67.0 28.8
California 580.0 840.0 44.8
Colorado 63.0 92.0 46.0
Connecticut 72.0 91.0 26.4
Delaware 16.0 23.0 43.8
District of
Columbia
9.2 9.0 -2.2
Florida 480.0 720.0 50.0
Georgia 130.0 190.0 46.2
Hawaii 25.0 35.0 40.0
Idaho 22.0 33.0 50.0
Illinois 210.0 260.0 23.8
Indiana 100.0 130.0 30.0
Iowa 62.0 73.0 17.7
Kansas 50.0 62.0 24.0
Kentucky 67.0 86.0 28.4
Louisiana 81.0 110.0 35.8
Maine 25.0 35.0 40.0
Maryland 97.0 130.0 34.0
Massachusetts 120.0 150.0 25.0
Michigan 170.0 220.0 29.4
Minnesota 88.0 120.0 36.4
Mississippi 51.0 65.0 27.5
Missouri 110.0 130.0 18.2
Montana 18.0 27.0 50.0
Nebraska 33.0 40.0 21.2
Nevada 37.0 64.0 73.0
New Hampshire 22.0 32.0 45.5
New Jersey 170.0 210.0 23.5
New Mexico 34.0 53.0 55.9
New York 380.0 460.0 21.1
North Carolina 150.0 210.0 40.0
North Dakota 14.0 16.0 14.3
Ohio 210.0 250.0 19.0
Oklahoma 60.0 76.0 26.7
Oregon 59.0 84.0 42.4
Pennsylvania 270.0 320.0 18.5
Rhode Island 22.0 27.0 22.7
South Carolina 79.0 120.0 51.9
South Dakota 16.0 20.0 25.0
Tennessee 110.0 140.0 27.3
Texas 330.0 490.0 48.5
Utah 28.0 42.0 50.0
Vermont 11.0 17.0 54.5
Virginia 130.0 190.0 46.2
Washington 97.0 140.0 44.3
West Virginia 36.0 44.0 22.2
Wisconsin 100.0 130.0 30.0
Wyoming 8.5 13.0 52.9
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pared with a 17% chance for men. As shown in Fig. 3,
for AD specifically, the estimated lifetime risk at the
age of 65 years was nearly one in six (17.2%) for
women compared with nearly 1 in 11 (9.1%) for men[142]. As previously noted, these differences in lifetime
risks between women and men are largely due to
women’s longer life expectancy.
The definition of AD and other dementias used in the Fra-
mingham Study required documentation of moderate-to-
severe disease and symptoms lasting a minimum of 6
months. Using a definition that also includes milder disease
and disease of less than 6 months’ duration, lifetime risks of
AD and other dementias would be much higher than those
estimated by this study.3.4. Estimates of the number of people with AD by state
Table 2 summarizes the projected number of people aged
65 years and older with AD (prevalent cases of AD) by state
for 2014 and the projected percentage change in the number
of people with AD between 2014 and 2025.A10 (Note: the
total number of people with AD is larger for states with
larger populations such as California and New York.)
Comparable estimates and projections for other types of
dementia are not available.
As shown in Fig. 4, between 2014 and 2025, every state
and region across the country is expected to experience
double-digit percentage increases in the numbers of people
with AD because of increases in the population aged 65
years and older. The West and Southeast are expected to
experience the largest increases in numbers of people
with AD between 2014 and 2025. The increasing number
of individuals with AD will have a marked impact on
states’ health-care systems, as well as on families and
caregivers.3.5. Looking to the future
The number of Americans surviving into their 80s, 90s,
and beyond is expected to grow dramatically because of ad-
vances in medicine and medical technology, as well as so-
cial and environmental conditions [143]. Additionally, a
large segment of the American population—the baby
boom generation—has begun to reach the age range of
elevated risk for AD and other dementias, with the first
baby boomers having reached the age of 65 years in
2011. By 2030, the segment of the US population aged 65
years and older is expected to grow dramatically, and the
estimated 72 million older Americans will make up
approximately 20% of the total population (up from 13%
in 2010) [143].
As the number of older Americans grows rapidly, so too
will the numbers of new and existing cases of AD, as shown
in Fig. 5 [114].A11
 In 2000, there were an estimated 411,000 new cases of
AD. For 2010, that number was estimated to be
454,000 (a 10% increase); by 2030, it is projected to
be 615,000 (a 50% increase from 2000); and by
2050, 959,000 (a 130% increase from 2000) [140].
Fig. 4. Projected changes between 2014 and 2025 in AD prevalence by state. Change from 2014 to 2025 for Washington, D.C.: -2.2%. Created from unpub-
lished data provided to the Alzheimer’s Association by Hebert et al.A10
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with AD is estimated to reach 7.1 million—a 40% in-
crease from the 5 million aged 65 years and older cur-
rently affected [114].A12
 By 2050, the number of people aged 65 years and older
with AD may nearly triple, from 5 million to a pro-
jected 13.8 million, barring the development of medi-
cal breakthroughs to prevent, slow, or stop the
disease [114].A11 Previous estimates based on high-
range projections of population growth provided by
the US Census suggest that this number may be as
high as 16 million [144].A13
Longer life expectancies and aging baby boomers
will also increase the number and percentage of Amer-
icans who will be among the oldest old. Between 2010
and 2050, the oldest old are expected to increase from
14% of all people aged 65 years and older in the United
States to 20% of all people aged 65 years and older
[143]. This will result in an additional 13 million
oldest old people—individuals at the highest risk for
developing AD [143]. In 2014, the population aged 85 years and older in-
cludes about 2 million people with AD or 40% of all
people with AD aged 65 years and older [114].
 When the first wave of baby boomers reaches the age of
85 years (in 2031), it is projected that more than 3 mil-
lion people aged 85 years and older will have AD [114].
 By 2050, there could be as many as 7 million people
aged 85 years and older with AD, accounting for
half (51%) of all people aged 65 years and older with
AD [114].4. Mortality and morbidity
AD is officially listed as the sixth leading cause of death
in the United States [145]. It is the fifth leading cause of
death for those aged 65 years and older [145]. However, it
may cause even more deaths than official sources
recognize. In addition to being a leading cause of death,
AD is a leading cause of disability and poor health
(morbidity). Before a person with AD dies, he or she lives
through years of morbidity as the disease progresses.
Fig. 5. The projected number of people aged 65 years or older (total and by age group) in the United States population with AD, 2010 to 2050. Created from data
from Hebert et al. [114].A11
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It is difficult to determine how many deaths are caused by
AD each year because of theway causes of death are recorded.
According to final data from the National Center for Health
Statistics of the CDC, 83,494 people died from AD in 2010
(the most recent year for which final data are available)
[145]. The CDC considers a person to have died from AD if
the death certificate lists AD as the underlying cause of
death, defined by the World Health Organization as “the
disease or injury which initiated the train of events leading
directly to death” [146]. However, death certificates for
individuals with AD often list acute conditions such as
pneumonia as the primary cause of death rather than AD
[147–149]. Severe dementia frequently causes complications
such as immobility, swallowing disorders, and malnutrition
that can significantly increase the risk of other serious
conditions that can cause death. One such condition is
pneumonia, which has been found in several studies to be the
most commonly identified cause of death among elderly
people with AD and other dementias [150,151]. The number
of people with AD who die while experiencing these other
conditions may not be counted among the number of people
who died from AD according to the CDC definition, although
AD is likely a contributing cause of death. Thus, it is likely
that AD is a contributing cause of death for more Americans
than is indicated by CDC data.
The situation has been described as a “blurred distinction
between death with dementia and death from dementia”
[152]. According to data from the CHAP, an estimated
600,000 people aged 65 years and older died with AD in the
United States in 2010, meaning they died after developing
AD [153].A14 Of these, an estimated 400,000 were aged 85
years and older and an estimated 200,000 were aged 65 to84 years. Other investigators, using data from the Rush
Memory and Aging Project and the Religious Orders Study,
estimated that 500,000 deaths among people aged 75 years
and older were attributed to AD in the United States in 2010
(estimates for people aged 65 to 74 years were not available)
[154]. Furthermore, according to Medicare data, one-third of
all seniors who die in a given year have been diagnosed
with AD or another dementia [139,155]. Although some
seniors who die with AD die from causes that are unrelated
to AD, many of them die from AD itself or from conditions
in which AD was a contributing cause such as pneumonia. A
recent study evaluating the contribution of individual
common diseases to death using a nationally representative
sample of older adults found that dementia was the second
largest contributor to death behind heart failure [156]. Thus,
for people who die with AD, the disease is expected to be
a significant direct contributor to their deaths.
Based on CHAP data, an estimated 700,000 people in the
United States aged 65 years or older will diewithAD in 2014
[153].A14 The true number of deaths caused by AD is likely
to be somewhere between the official estimated numbers of
those dying from AD (as indicated by death certificates) and
those dying with AD. Regardless of the cause of death,
among people aged 70 years, 61% of those with AD are
expected to die before the age of 80 years compared with
30% of people without AD [157].4.2. Public health impact of deaths from AD
As the population of the United States ages, AD is becom-
ing a more common cause of death. Although deaths from
other major causes have decreased significantly, deaths
from AD have increased significantly. Between 2000 and
2010, deaths attributed to AD increased 68%, whereas those
Fig. 6. Percentage changes in selected causes of death (all ages) between 2000 and 2010.Created fromdata from theNationalCenter forHealth Statistics [145, 158].
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creased 16% (Fig. 6) [145,158]. The increase in the number
and proportion of death certificates listing AD as the
underlying cause of death reflects both changes in patterns
of reporting deaths on death certificates over time and an
increase in the actual number of deaths attributable to AD.
Another way to describe the impact of AD on mortality is
through a statistic known as population-attributable risk. It
represents the proportion of deaths (in a specified amount
of time) in a population that may be preventable if a disease
were eliminated. The population-attributable risk of AD on
mortality over 5 years in people aged 65 years and older is
estimated to be between 5% and 15% [159,160]. This
means that over the next 5 years, 5% to 15% of all deaths
in older people can be attributed to AD.4.3. State-by-state deaths from AD
Table 3 provides information on the number ofdeaths due to
AD by state in 2010, the most recent year for which state-by-
state data are available. This information was obtained from
death certificates and reflects the condition identified by the
physician as the underlying cause of death. The table also pro-
vides annual mortality rates by state to compare the risk of
death due to AD across states with varying population sizes
and attributes. For the United States as a whole, in 2010, the
mortality rate for AD was 27 deaths per 100,000 people [145].4.4. Death rates by age
Although people younger than 65 years can develop and
die from AD, the highest risk of death from AD is in peopleaged 65 years or older. As listed in Table 4, death rates for
AD increase dramatically with age. The increase in deaths
attributed to AD over time has disproportionately affected
the oldest old. Between 2000 and 2010, death rates from
AD increased 6% for people aged 65 to 74 years, 32% for
people aged 75 to 84 years, and 48% for people aged 85
years and older [161].4.5. Duration of illness from diagnosis to death
Studies indicate that people aged 65 years and older sur-
vive an average of 4 to 8 years after a diagnosis of AD, yet
some live as long as 20 years with AD [160,162–166].
This indicates the slow, insidious nature of the progression
of AD. On average, a person with AD will spend more
years (40% of the total number of years with AD) in the
most severe stage of the disease than in any other stage
[157]. Much of this time will be spent in a nursing home,
as nursing home admission by age 80 years is expected for
75% of people with AD compared with only 4% of the
general population [157]. In all, an estimated two-thirds of
those dying of dementia do so in nursing homes compared
with 20% of people with cancer and 28% of people dying
from all other conditions [167].4.6. Burden of AD
The long duration of illness before death contributes sig-
nificantly to the public health impact of AD because much of
that time is spent in a state of disability and dependence. Sci-
entists have developed methods to measure and compare the
burden of different diseases on a population in a way that
Table 4
US annual Alzheimer’s disease death rates (per 100,000) by age
Age (y) 2000 2002 2004 2006 2008 2010
45–54 0.2 0.1 0.2 0.2 0.2 0.3
55–64 2.0 1.9 1.8 2.1 2.2 2.1
65–74 18.7 19.6 19.5 19.9 21.1 19.8
75–84 139.6 157.7 168.5 175.0 192.5 184.5
851 667.7 790.9 875.3 923.4 1002.2 987.1
Total death rate* 18.1 20.8 22.6 23.7 25.8 25.1
*Reflects the overall death rate for ages 45 years and older.
NOTE. Created from data from the National Center for Health Statistics
[161].
Table 3
Number of deaths and annual mortality rate (per 100,000) due to
Alzheimer’s disease by state, 2010
State Number of deaths Mortality rate
Alabama 1523 31.9
Alaska 85 12.0
Arizona 2327 36.4
Arkansas 955 32.8
California 10,856 29.1
Colorado 1334 26.5
Connecticut 820 22.9
Delaware 215 23.9
District of Columbia 114 18.9
Florida 4831 25.7
Georgia 2080 21.5
Hawaii 189 13.9
Idaho 410 26.2
Illinois 2927 22.8
Indiana 1940 29.9
Iowa 1411 46.3
Kansas 825 28.9
Kentucky 1464 33.7
Louisiana 1295 28.6
Maine 502 37.8
Maryland 986 17.1
Massachusetts 1773 27.1
Michigan 2736 27.7
Minnesota 1451 27.4
Mississippi 927 31.2
Missouri 1986 33.2
Montana 302 30.5
Nebraska 565 30.9
Nevada 296 11.0
New Hampshire 396 30.1
New Jersey 1878 21.4
New Mexico 343 16.7
New York 2616 13.5
North Carolina 2817 29.5
North Dakota 361 53.7
Ohio 4109 35.6
Oklahoma 1015 27.1
Oregon 1300 33.9
Pennsylvania 3591 28.3
Rhode Island 338 32.1
South Carolina 1570 33.9
South Dakota 398 48.9
Tennessee 2440 38.4
Texas 5209 20.7
Utah 375 13.6
Vermont 238 38.0
Virginia 1848 23.1
Washington 3025 45.0
West Virginia 594 32.1
Wisconsin 1762 31.0
Wyoming 146 25.9
US total 83,494 27.0
NOTE. Created from data from the National Center for Health Statistics
[145].A15
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cause of that disease and the number of healthy years of
life lost by virtue of being in a state of disability. These
measures indicate that AD is a very burdensome diseaseand that the burden of AD has increased more dramatically
in the United States in recent years than other diseases. The
primary measure of disease burden is called disability-
adjusted life-years, which is the sum of the number of years
of life lost because of premature mortality and the number of
years lived with disability. Based on disability-adjusted life-
years, between 1990 and 2010, AD rose from the 25th most
burdensome disease in the United States to the 12th; no other
disease or condition increased that much [168]. Looking at
years of life lost, AD rose from 32nd to 9th, the largest
increase for any disease. Looking at years lived with
disability, AD went from ranking 17th to 12th; only
kidney disease equaled AD in as high a jump in rank.
Taken together, the numbers in this section indicate that
AD is not only responsible for the deaths of more and
more Americans, but also contributes to more and more
cases of poor health and disability in the United States.5. Caregiving
Caregiving refers to attending to another individual’s
health needs. Caregiving often includes assistance with
one or more ADLs (such as bathing and dressing)
[169,170]. More than 15 million Americans provide
unpaid care for people with AD and other dementias.A165.1. Unpaid caregivers
Unpaid caregivers are usually immediate family members,
but they alsomay be other relatives and friends. In 2013, these
individuals provided an estimated 17.7 billion hours of infor-
mal (i.e., unpaid) care, a contribution to the nation valued at
over $220.2 billion. This is approximately half of the net value
of Walmart sales in 2012 ($443.9 billion) [171] and nearly
eight times the total revenue of McDonald’s in 2012 ($27.6
billion) [172]. According to a recent report [173], the value
of informal care was nearly equal to the direct medical and
long-term care costs of dementia. Eighty-five percent of
help provided to all older adults in the United States is from
family members [174].
5.1.1. Who are the caregivers?
Several sources have examined the demographic back-
ground of family caregivers of people with AD and other
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surveys conducted in eight states and the District of
Columbia [175] found that 65% of caregivers of people
with AD and other dementias were women; 21% were
aged 65 years and older; 44% had some college education
or had received a degree; 64% were currently employed, a
student, or a homemaker; and 71% were married or in a
long-term relationship [175].
ADAMS, based on a nationally representative subsam-
ple of older adults from the Health and Retirement Survey
[176], compared two types of “primary” caregivers
(individuals who indicate having the most responsibility
for helping their relatives): those caring for people with
dementia and those caring for people with cognitive
problems who did not reach the threshold of dementia.
The primary caregiver groups did not differ significantly
by age (60 vs. 61 years, respectively), gender (71% vs.
81% female), race (66% vs. 71% non-Hispanic white), or
marital status (70% vs. 71% married). Over half of primary
caregivers (55%) of people with dementia took care of pa-
rents [177].5.1.2. Ethnic and racial diversity in caregiving
Among caregivers of people with AD and other demen-
tias, the National Alliance for Caregiving (NAC) and
AARP found the following [178]:
 Fifty-four percent of white caregivers assist a parent
compared with 38% of individuals from other racial/
ethnic groups.
 On average, Hispanic and African-American care-
givers spend more time caregiving (approximately
30 h/wk) than non-Hispanic white caregivers
(20 h/wk) and Asian-American caregivers (16 h/wk).
 Hispanic (45%) and African-American (57%) care-
givers are more likely to experience high burden
from caregiving than whites (33%) and Asian-
Americans (30%).Table 5
Dementia caregiving tasks
Help with IADLs such as household chores, shopping, preparing meals, providing
legal affairs, and answering the telephone.
Helping the person take medications correctly, either via reminders or direct adm
Helping the person adhere to treatment recommendations for dementia or other m
Assisting with personal ADLs such as bathing, dressing, grooming, feeding, and he
incontinence.
Managing behavioral symptoms of the disease such as aggressive behavior, wand
disturbances.
Finding and using support services such as support groups and adult day service
Making arrangements for paid in-home, nursing home, or assisted living care.
Hiring and supervising others who provide care.
Assuming additional responsibilities that are not necessarily specific tasks such a
 Providing overall management of getting through the day.
 Addressing family issues related to caring for a relativewith Alzheimer’s dis
decision making, and arrangements for respite for the main caregiver.
Abbreviation: IADLs, instrumental activities of daily living; ADLs, activities o5.1.3. Sandwich generation caregivers
Traditionally, the term “sandwich generation caregiver”
has referred to a middle-aged person who simultaneously
cares for dependent minor children and aging parents. This
phenomenon has received a good deal of attention in recent
years, as it has been argued that demographic changes (such
as parents of dependent minors being older than in the past
and the aging of the US population) have led to increases in
the number of sandwich generation caregivers [179–181].
NAC/AARP found that 30% of AD and dementia caregivers
had children under the age of 18 years living with them
[178]. Other studies have found that sandwich generation
caregivers are present in 8% to 13% of households in the
United States [182,183]. It is not clear what proportion of
care recipients in these studies had AD or another dementia,
but in other studies, about one-third of elderly care recipients
have AD or another dementia [184]. Various studies have
concluded that sandwich generation caregivers experience
unique challenges related to the demands of providing care
for both aging parents and dependent children. Such
challenges include limited time, energy, and financial
resources [180,185,186]. Some authors have therefore
concluded that sandwich generation caregivers can
experience anxiety and depression as well as lower quality
of life due to the unique challenges these individuals
experience [186,187].
5.1.4. Caregiving tasks
The care provided to peoplewith AD and other dementias
is wide ranging and in some instances all-encompassing.
Table 5 summarizes some of the most common types of
dementia care provided.
Although the care provided by family members of people
with AD and other dementias is somewhat similar to the help
provided by caregivers of people with other conditions, de-
mentia caregivers tend to provide more extensive assistance.
Family caregivers of people with dementia are more likely
than caregivers of other older people to assist with anytransportation, arranging for doctor’s appointments, managing finances and
inistration of medications.
edical conditions.
lping the person walk, transfer from bed to chair, use the toilet, and manage
ering, depressive mood, agitation, anxiety, repetitive activity, and nighttime
programs.
s
ease, including communication with other family members about care plans,
f daily living.
Fig. 7. Proportion of caregivers of peoplewith AD and other dementias versus caregivers of other older people who provide help with specific activities of daily
living, United States, 2009. Created from data from the National Alliance for Caregiving and AARP [178].
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providing help with getting in and out of bed, and about one-
third provide help to their care recipients with getting to and
from the toilet, bathing, managing incontinence, and feed-
ing. These findings are consistent with the heightened degree
of dependency experienced by some people with AD and
other dementias. Fewer caregivers of other older people re-
port providing help with each of these types of care [178].
In addition to assisting with ADLs, almost two-thirds of
caregivers of people with AD and other dementias advocate
for their care recipient with government agencies and service
providers (64%), and nearly half arrange and supervise paid
caregivers from community agencies (46%). By contrast,
caregivers of other older adults are less likely to advocate
for their family member (50%) and supervise community-
based care (33%) [178]. Caring for a person with dementia
also means managing symptoms that family caregivers of
people with other diseases may not face such as
neuropsychiatric symptoms and severe behavioral problems.
When persons with AD or another dementiamove to an as-
sisted living residence or a nursing home, the help provided by
their family caregiver usually changes from the comprehen-
sive care summarized in Table 5 to providing emotional
support, interacting with facility staff, and advocating for
appropriate care. However, some family caregivers
continue to help with bathing, dressing, and other ADLs
[188–190]. Admitting a relative to a residential
care setting has mixed effects on the emotional and
psychological well-being of family caregivers. Some studies
suggest that distress remains unchanged or even increases
after a relative is admitted to a residential care facility, but
other studies have found that distress declines significantly
after admission [190,191]. The relationship between the
caregiver and the person with dementia may explain thesediscrepancies. For example, husbands, wives, and daughters
are significantly more likely than other family caregivers to
indicate persistent burden up to 12 months after placement,
and husbands are more likely than other family caregivers
to indicate persistent depression up to a year after a
relative’s admission to a residential care facility [191].
5.1.5. Duration of caregiving
Caregivers of peoplewith AD and other dementias provide
care for a longer time, on average, than do caregivers of older
adults with other conditions. As shown in Fig. 8, 43% of
caregivers of people with AD and other dementias provide
care for 1 to 4 years compared with 33% of caregivers of
people without dementia. Similarly, 32% of dementia
caregivers provide care for over 5 years compared with
28% of caregivers of people without dementia [178].
5.1.6. Hours of unpaid care and economic value of
caregiving
In 2013, 15.5million family and other unpaid caregivers of
people with AD and other dementias provided an estimated
17.7 billion hours of unpaid care. This number represents
an average of 21.9 hours of care per caregiver per week or
1139 hours of care per caregiver per year.A18 With this care
valued at $12.45 per hour,A19 the estimated economic value
of care provided by family and other unpaid caregivers of peo-
ple with dementia was $220.2 billion in 2013. Table 6 lists the
total hours of unpaid care and the value of care provided by
family and other unpaid caregivers for the United States and
each state. Unpaid caregivers of people with AD and other
dementias provide care valued at more than $1 billion in
each of 39 states. Unpaid caregivers in each of the four
most populous states—California, Florida, New York, and
Texas—provided care valued at more than $14 billion.
Fig. 8. Proportion of AD and dementia caregivers versus caregivers of other older people by duration of caregiving, United States, 2009. Created from data from
the National Alliance for Caregiving and AARP [178].
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those who indicate the most responsibility in caring for
their relatives) provide particularly extensive amounts of
care. For example, a 2011 report from ADAMS found
that primary family caregivers of people with dementia re-
ported spending an average of 9 h/d providing help to their
relatives [177].
5.1.7. Impact of AD caregiving
Caring for a person with AD or another dementia poses
special challenges. For example, people with AD experience
losses in judgment, orientation, and the ability to understand
and communicate effectively. Family caregivers must often
help people with AD manage these issues. The personality
and behavior of a person with AD are affected as well, and
these changes are often among the most challenging for fam-
ily caregivers [192]. Individuals with dementia may also
require increasing levels of supervision and personal care
as the disease progresses. As symptoms worsen with the
progression of a relative’s dementia, the care required of
family members can result in increased emotional stress,
depression, impaired immune system response, health
impairments, lost wages due to disruptions in employment,
and depleted income and finances [193–198].A17 The
intimacy and history of experiences and memories that are
often part of the relationship between a caregiver and care
recipient may also be threatened because of the memory
loss, functional impairment, and psychiatric/behavioral
disturbances that can accompany the progression of AD.
5.1.7.1. Caregiver emotional well-being
Although caregivers report some positive feelings about
caregiving, including family togetherness and the satisfac-
tion of helping others [199],A17 they also report high levels
of stress over the course of providing care: Based on a Level of Care Index that combined the
number of hours of care and the number of ADL tasks
performed by the caregiver, fewer dementia caregivers
in the 2009 NAC/AARP survey were classified in the
lowest level of burden than caregivers of people with-
out dementia (16% vs. 31%, respectively) [178].
 Fifty-nine percent of family caregivers of people with
AD and other dementias rated the emotional stress of
caregiving as high or very high (Fig. 9).A17
 Many family caregivers report “a good amount” to “a
great deal” of caregiving strain concerning financial is-
sues (47%) and family relationships (52%).A17
 Earlier research in smaller samples found that over
one-third (39%) of caregivers of people with dementia
suffered from depression compared with 17% of non-
caregivers [200,201]. A meta-analysis of research
comparing caregivers affirmed this disparity in the
prevalence of depression between caregivers of people
with dementia and noncaregivers [197]. In the
ADAMS sample, 44% of primary caregivers of
people with dementia indicated depressive symptoms
compared with 27% of primary caregivers of people
who had cognitive impairment but no dementia
[177]. Among family members supporting an older
person who has MCI, 23% were found to have
depression [202], a much higher percentage than
found in the general population (7%) [203]. In a
small, recent study of dementia family caregiving
and hospitalization [204], clinical depression rates of
63% and 43% were found among family caregivers
of people with dementia who were or were not
hospitalized, respectively.
 In the 2009 NAC/AARP survey, caregivers most likely
to indicate stress were women, older, residing with the
care recipient, and white or Hispanic. In addition, these
Table 6
Number of Alzheimer’s disease and dementia (AD/D) caregivers, hours o
unpaid care, economic value of the care, and higher health-care costs of
caregivers by state, 2013
State
AD/D
caregivers
(in thousands)
Hours of
care per year
(in millions)
Value of
unpaid care
(in millions
of dollars)
Higher
caregiver
health-care
costs (in
millions
of dollars)
Alabama 299 341 $4240 $164
Alaska 33 37 $466 $26
Arizona 307 350 $4358 $147
Arkansas 173 197 $2455 $94
California 1547 1761 $21,927 $853
Colorado 229 261 $3254 $121
Connecticut 176 201 $2497 $134
Delaware 52 59 $732 $39
District of
Columbia
27 31 $381 $25
Florida 1037 1181 $14,709 $654
Georgia 499 569 $7080 $240
Hawaii 64 73 $910 $39
Idaho 77 88 $1091 $38
Illinois 587 668 $8322 $350
Indiana 330 376 $4686 $194
Iowa 133 151 $1884 $81
Kansas 149 170 $2112 $89
Kentucky 267 304 $3789 $155
Louisiana 228 260 $3237 $137
Maine 68 77 $964 $51
Maryland 286 326 $4056 $189
Massachusetts 325 370 $4610 $266
Michigan 505 575 $7163 $294
Minnesota 245 280 $3481 $161
Mississippi 205 233 $2900 $117
Missouri 310 354 $4402 $190
Montana 48 54 $677 $28
Nebraska 80 91 $1134 $50
Nevada 137 156 $1938 $69
New Hampshire 65 74 $919 $45
New Jersey 443 505 $6287 $296
New Mexico 105 120 $1495 $62
New York 1010 1150 $14,316 $742
North Carolina 442 504 $6272 $252
North Dakota 29 33 $415 $20
Ohio 591 674 $8386 $369
Oklahoma 218 248 $3093 $125
Oregon 173 196 $2446 $100
Pennsylvania 669 762 $9492 $456
Rhode Island 52 60 $744 $38
South Carolina 291 331 $4127 $161
South Dakota 37 42 $521 $23
Tennessee 418 476 $5922 $235
Texas 1302 1482 $18,457 $679
Utah 140 159 $1980 $62
Vermont 30 34 $422 $20
Virginia 447 509 $6342 $247
Washington 319 363 $4518 $191
West Virginia 108 123 $1536 $73
Wisconsin 190 217 $2698 $122
Wyoming 28 31 $392 $17
US total 15,533 17,689 $220,233 $9332
Created from data from the 2009 BRFSS, U.S. Census Bureau, Center
for Medicare and Medicaid Services, National Alliance for Caregiving
AARP, and U.S. Department of Labor. A13, A16, A17, A18
NOTE. State totals may not add up to US total due to rounding.
Fig. 9. Proportion of AD and dementia caregivers who report high or very
high emotional and physical stress due to caregiving. Created from data
from the Alzheimer’s Association.A17
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s
,caregivers often believed there was no choice in taking
on the role of caregiver [178].
 When caregivers report being stressed because of the
impaired person’s behavioral symptoms, it increases
the chance that they will place the care recipient in a
nursing home [178,205].
 Seventy-six percent of family caregivers of people
with AD and other dementias said that they some-
what agree or strongly agree that it is “neither right
nor wrong” when families decide to place their fam-
ily member in a nursing home. Yet many such care-
givers experience feelings of guilt, emotional
upheaval, and difficulties in adapting to admission
(e.g., interacting with care staff to determine an
appropriate care role for the family member)
[188,190,206,207].A17
 The demands of caregiving may intensify as people
with dementia approach the end of life [208]. In the
year before the person’s death, 59% of caregivers
felt they were “on duty” 24 hours a day, and many
felt that caregiving during this time was extremely
stressful [209]. One study of end-of-life care found
that 72% of family caregivers said they experienced
relief when the person with AD or another dementia
died [209].5.1.7.2. Caregiver physical health
For some caregivers, the demands of caregiving may
cause declines in their own health. Thirty-eight percent of
caregivers of people with AD and other dementias reported
that the physical impact of caregiving was high to very high
(Fig. 9).A17 Sleep disturbances, which can occur frequently
when caring for a relative with AD or dementia, have also
been shown to negatively influence family caregivers’
health [210].
5.1.7.2.1. General health
Seventy-four percent of caregivers of people with AD and
other dementias reported that they were “somewhat con-
cerned” to “very concerned” about maintaining their own
Alzheimer’s Association / Alzheimer’s & Dementia 10 (2014) e47-e92e66health since becoming a caregiver.A17 Dementia caregivers
were more likely than noncaregivers to report that their
health was fair or poor [195]. Dementia caregivers were
also more likely than caregivers of other older people to
say that caregiving made their health worse [178,211].
Data from the 2009 and 2010 BRFSS caregiver surveys
found that 7% of dementia caregivers say the greatest
difficulty of caregiving is that it creates or aggravates their
own health problems compared with 2% of other
caregivers [175]. Other studies suggest that caregiving
tasks have the positive effect of keeping older caregivers
more physically active than noncaregivers [212].
5.1.7.2.2. Physiological changes
The chronic stress of caregiving is associated with phys-
iological changes that could increase the risk of developing
chronic conditions. For example, a series of recent studies
found that under certain conditions, some AD caregivers
were more likely to have elevated biomarkers of cardiovas-
cular disease risk and impaired kidney function risk than
those who were not caregivers [213–218].
Caregivers of a spouse with AD or another dementia are
more likely than married noncaregivers to have physiological
changes that may reflect declining physical health, including
high levels of stress hormones [219], reduced immune
function [193,220], slow wound healing [221], and increased
incidence of hypertension [222], coronary heart disease
[223], and impaired endothelial function (the endothelium is
the inner lining of the blood vessels). Some of these changes
may be associated with an increased risk of cardiovascular
disease [224]. Overall, the literature is fairly consistent in
suggesting that the chronic stress of dementia care can have
potentially negative influences on caregiver health.
5.1.7.2.3. Health-care utilization
The physical and emotional impact of dementia caregiv-
ing is estimated to have resulted in $9.3 billion in health-care
costs in the United States in 2013.A20 Table 6 lists the
estimated higher health-care costs for AD and dementia
caregivers in each state.
Dementia caregivers were more likely to visit the emer-
gency department or be hospitalized in the preceding 6
months if the care recipient was depressed, had low func-
tional status, or had behavioral disturbances than if the
care recipient did not exhibit these symptoms [225].
5.1.7.2.4. Mortality
The health of a person with dementia may also affect the
caregiver’s risk of dying, although studies have reported
mixed findings on this issue. In one study, caregivers of
spouses who were hospitalized and had dementia in their
medical records were more likely to die in the following
year than caregivers whose spouses were hospitalized but
did not have dementia, even after accounting for the age of
caregivers [226]. However, other studies have found that
caregivers have lower mortality rates than noncaregivers
[227,228]. One study reported that higher levels of stresswere associated with higher rates of mortality in both
caregivers and noncaregivers [228]. These findings suggest
that it is high stress, not caregiving per se, that increases
the risk of mortality. Such results emphasize that dementia
caregiving is a complex undertaking; simply providing
care to someone with AD or another dementia may not
consistently result in stress or health problems for
caregivers. Instead, the stress of dementia caregiving is
influenced by a number of other factors such as dementia
severity, how challenging caregivers perceive certain
aspects of care to be, available social support, and
caregiver personality. All these factors are important to
consider when understanding the health impact of caring
for a person with dementia [229].
5.1.7.3. Caregiver employment
Among caregivers of people with AD and other dementias,
75% reported being employed at any time since assuming
care responsibilities. Eighty-one percent of AD caregivers
younger than 65 years were employed, and 35% aged 65 years
and older were employed [178]. Employed dementia
caregivers indicate having to make major changes to their
work schedules because of their caregiving responsibilities.
Fifty-four percent said they had to go in late, leave early, or
take time off, and 15% had to take a leave of absence while
caregiving.A17 Other work-related changes pertaining to care-
giving are summarized in Fig. 10.
5.1.8. Caregiver interventions that may improve caregiver
outcomes
Intervention strategies to support family caregivers of
people with AD have been developed and evaluated. The
types and focus of these interventions are summarized in
Table 7 [230].
In general, these interventions aim to ameliorate negative
aspects of caregiving with the goal of improving the health
and well-being of dementia caregivers. Methods used to ac-
complish this objective include enhancing caregiver strat-
egies to manage dementia-related symptoms, bolstering
resources through enhanced social support, and providing
relief/respite from daily care demands. Desired outcomes
of these interventions include decreased caregiver stress
and depression and delayed nursing home admission of the
person with dementia.
Characteristics of effective caregiver interventions
include programs that are administered over long periods,
interventions that approach dementia care as an issue
for the entire family, and interventions that train dementia
caregivers in the management of behavioral problems
[231–234]. Multidimensional interventions appear
particularly effective. These approaches combine individual
consultation, family sessions and support, and ongoing
assistance to help caregivers manage changes that occur as
dementia progresses. Examples of successful multi-
dimensional interventions are the New York University
Caregiver Intervention [235,236], the Resources for
Fig. 10. Effect of caregiving on work: work-related changes among caregivers of people with AD and other dementias. Created from data from the Alzheimer’s
Association.A17
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[198,230,237–239], and the Savvy Caregiver program
[240–242]. Other multidimensional approaches that
recently have demonstrated promising results include
Partners in Dementia Care, a care coordination program
that enhances access to needed services and strengthens
the family care support network [243], and Acquiring New
Skills While Enhancing Remaining Strengths, a program
that incorporates caregiver skills training with cognitive
rehabilitation for the person with dementia [244].
Although less consistent in their demonstrated benefits,
support group strategies and respite services such as adult
day programs have the potential to offer encouragement or
relief to enhance caregiver outcomes. The effects of pharma-
cologic therapies for treating symptoms of dementia (e.g.,Table 7
Type and focus of caregiver interventions
Type of intervention Focus
Case management Provides assessment, information, plannin
Psychoeducational Includes a structured program that provid
expand skills to effectively respond to
and care-related needs). Includes lectu
specialized training.
Counseling Aims to resolve preexisting personal prob
care recipients and/or improve family
Support groups Less structured than psychoeducational or
to share personal feelings and concern
Respite Planned temporary relief for the caregiver
and in-home or institutional respite for
Training of the person with dementia Memory clinic or similar programs aimed
positive effect on caregiver outcomes.
Psychotherapeutic approaches Involves the establishment of a therapeut
cognitive-behavioral therapy for careg
distress, developing new behaviors to d
caregiver well-being).
Multicomponent approaches Intensive support strategies that combine m
single, long-term service (often provid
NOTE. Created from data from S€orensen et al. [230] and Pinquart et al. [260].acetylcholinesterase inhibitors, memantine, antipsychotics,
and antidepressants) also appear to modestly reduce care-
giver stress [245]. Mindfulness-based stress reduction (a
strategy to reduce stress through meditation techniques
that create attention focused on the moment and nonjudg-
mental awareness) has shown recent promise as an effective
approach to reduce dementia caregiver distress [246].
Structured, group-based, psychoeducational programs that
include both family care providers and care recipients with
early-stage AD have helped to improve feelings of prepara-
tion and confidence among family members and emotional
well-being among people with early-stage AD [247–249].
Several sources [230,234,235,250–255] recommend that
clinicians identify the risk factors and outcomes perceived
as important to each caregiver and select interventionsg, referral, care coordination, and/or advocacy for family caregivers.
es information about the disease, resources, and services and about how to
symptoms of the disease (i.e., cognitive impairment, behavioral symptoms,
res, discussions, and written materials and is led by professionals with
lems that complicate caregiving to reduce conflicts between caregivers and
functioning.
therapeutic interventions, support groups provide caregivers the opportunity
s to overcome feelings of social isolation.
through the provision of substitute care; examples include adult day services
a certain number of weekly hours.
at improving the competence of the care recipient, which may also have a
ic relationship between the caregiver and a professional therapist (e.g.,
ivers to focus on identifying and modifying beliefs related to emotional
eal with caregiving demands, and fostering activities that can promote
ultiple forms of interventions such as education, support, and respite into a
ed for 12 months or more).
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test the efficacy of intervention programs among different
caregiver groups to ensure their benefits for caregivers
across diverse clinical, racial, ethnic, socioeconomic, and
geographic contexts [256].
5.1.9. Caregiver interventions and their effects on people
with AD
Several reviews have sought to determine whether care-
giver interventions improve outcomes for people with AD
or other dementias. One recent review found that
caregiver-focused interventions are effective in reducing be-
havioral or psychiatric problems in people with dementia
[113]. Multidimensional interventions for dementia care-
givers have also been shown to prevent or delay nursing
home admission [112,257,258]. However, it is important to
note that these conclusions are not uniform; a recent
review that restricted its scope to high-quality evaluations
(i.e., randomized, controlled trials) indicated a lack of con-
sistent effects of caregiver interventions on people with
AD and other dementias [259].5.2. Paid caregivers5.2.1. Direct-care workers for people with AD and other
dementias
Direct-care workers such as nurse aides, home health
aides, and personal and home care aides comprise most of
the formal long-term care delivery system for older adults
(including those with AD and other dementias). In nursing
homes, nursing assistants make up the majority of staff
who work with cognitively impaired residents [261–263].
Most nursing assistants are women, and they come from
increasingly diverse ethnic, racial, and international
backgrounds. Nursing assistants help with bathing, dressing,
housekeeping, food preparation, and other activities.
Direct-care workers have difficult jobs, and they may not
receive the training necessary to provide dementia care
[262,264]. One review found that direct-care workers re-
ceived, on average, 75 hours of training that included little
focus on issues specific or pertinent to dementia care
[262]. Turnover rates are high among direct-care workers,
and recruitment and retention are persistent challenges
[265]. Reviews have shown that staff training programs to
improve the quality of dementia care in nursing homes
have modest positive benefits [266,267].
5.2.2. Shortage of geriatric health-care professionals in the
United States
Professionals who may receive special training in caring
for older adults include physicians, physician assistants,
nurses, social workers, pharmacists, case workers, and
others [265]. It is projected that the United States will
need an additional 3.5 million health-care professionals by
2030 just to maintain the current ratio of health-care profes-sionals to the older population [265]. The need for health-
care professionals trained in geriatrics is escalating, but
few providers choose this career path. It is estimated that
the United States has approximately half the number of cer-
tified geriatricians that it currently needs [268]. In 2010,
there were 4278 physicians practicing geriatric medicine
in the United States [269]. An estimated 36,000
geriatricians will be required to adequately meet the needs
of older adults in the United States by 2030 [265]. Other
health-related professions also have low numbers of geriatric
specialists relative to the population’s needs. According to
the Institute of Medicine, less than 1% of registered nurses,
physician assistants, and pharmacists identify themselves as
specializing in geriatrics [265]. Similarly, although 73% of
social workers serve clients aged 55 years and older and
about 8% of social workers are employed in long-term
care settings, only 4% have formal certification in geriatric
social work [265]. The complex care challenges of many
people with dementia often require the simultaneous
expertise of professionals trained in multiple care
disciplines. There is a continuing need for
interprofessional collaboration and education to enhance
the overall care of people with dementia [270].6. Use and costs of health care, long-term care, and
hospice
The costs of health care, long-term care, and hospice for
individuals with AD and other dementias are substantial, and
AD is one of the costliest chronic diseases to society [173].
Total payments in 2014 (in 2014 dollars) for all individuals
with AD and other dementias are estimated at $214 billion
(Fig. 11). Medicare and Medicaid are expected to cover
$150 billion, or 70%, of the total health-care and long-
term care payments for peoplewith AD and other dementias.
Out-of-pocket spending is expected to be $36 billion, or 17%
of total payments.A21 Unless otherwise indicated, all costs in
this section are reported in 2013 dollars.A226.1. Payments for health care, long-term care, and hospice
Table 8 reports the average annual per-person payments
for health-care and long-term care services for Medicare
beneficiaries with and without AD and other dementias. To-
tal per-person payments from all sources for health care and
long-term care for Medicare beneficiaries with AD and other
dementias were three times as great as payments for other
Medicare beneficiaries in the same age group ($46,669 per
person for those with dementia compared with $14,772 per
person for those without dementia) [155].A23
Twenty-nine percent of older individuals with AD and
other dementias who have Medicare also have Medicaid
coverage compared with 11% of individuals without demen-
tia [155]. Medicaid pays for nursing home and other long-
term care services for some people with very low income
and low assets, and the high use of these services by people
Fig. 11. Aggregate costs of care by payer for Americans aged 65 years o
older with AD and other dementias, 2014. Data are in 2014 dollars. “Other”
payment sources include private insurance, health maintenance organiza
tions, other managed care organizations, and uncompensated care. Created
from data from the application of the Lewin modelA21 to data from theMed
icare Current Beneficiary Survey for 2008 [155].
Table 8
Average annual per-person payments for health care and long-term care ser
disease and other dementias and by the place of residence, in 2013 dollars
Payment source
Beneficiaries with Alzheimer’s disease and o
Overall Community dwellin
Medicare $21,095 $18,787
Medicaid 10,771 237
Uncompensated 290 417
HMO 1058 1642
Private insurance 2407 2645
Other payer 964 174
Out of pocket 9970 3370
Total* 46,669 27,465
Abbreviation: HMO, health maintenance organization.
*Payments from sources do not equal total payments exactly due to the ef
and other dementias include payments for community-dwelling and facili
NOTE. Created from unpublished data from the Medicare Current Benefi
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-with dementia translates into high costs for the Medicaid
program. Average Medicaid payments per person for Medi-
care beneficiaries with AD and other dementias ($10,771)
were 19 times as great as average Medicaid payments for
Medicare beneficiaries without AD and other dementias
($561; Table 8) [155].
Despite these and other sources of financial assistance, in-
dividuals with AD and other dementias still incur high out-
of-pocket costs. These costs are for Medicare and other
health insurance premiums and for deductibles, copayments,
and services not covered by Medicare, Medicaid, or addi-
tional sources of support. Medicare beneficiaries aged 65
years and older with AD and other dementias paid $9970
out of pocket on average for health-care and long-term
care services not covered by other sources (Table 8) [155].
Average per-person out-of-pocket payments were highestvices, M
ther dem
g
fect of p
ty-dwel
ciary Su($19,196 per person) for individuals living in nursing homes
and assisted living facilities and were almost six times as
great as the average per-person payments for individuals
with AD and other dementias living in the community [155].
Recently, researchers evaluated the incremental health-
care and caregiving costs of dementia (i.e., the costs specif-
ically attributed to dementia for people with the same
coexisting medical conditions and demographic characteris-
tics) [173,271]. One group of researchers found that the
incremental health-care and nursing home costs for those
with dementia was $31,141 [173].A24
6.2. Use and costs of health-care services
Peoplewith AD and other dementias havemore than three
times as many hospital stays per year as other older people
[155]. Moreover, the use of health-care services for people
with other serious medical conditions is strongly affected
by the presence or absence of dementia. In particular, people
with coronary artery disease, diabetes, chronic kidney dis-
ease, chronic obstructive pulmonary disease (COPD), stroke,
or cancer who also have AD and other dementias have higher
use and costs of health-care services than people with these
medical conditions but no coexisting dementia.
6.2.1. Use of health-care services
Older people with AD and other dementias have more
hospital stays, skilled nursing facility stays, and home
health-care visits than other older people.
 Hospital: There are 780 hospital stays per 1000 Medi-
care beneficiaries aged 65 years and older with AD and
other dementias compared with 234 hospital stays per
1000 Medicare beneficiaries aged 65 years and older
without these conditions [155]. The most common
reasons for hospitalization of people with AD include
syncope (fainting), fall, and trauma (26%); ischemic
heart disease (17%); and gastrointestinal disease
(9%; Fig. 12) [272].edicare beneficiaries aged 65 years and older, with and without Alzheimer’s
entias by place of residence
Residential facility
Beneficiaries without Alzheimer’s
disease and other dementias
$24,319 $8005
25,494 561
114 328
241 1543
2074 1619
2067 153
19,196 2431
73,511 14,772
opulationweighting. Payments for all beneficiaries with Alzheimer’s disease
ling beneficiaries.
rvey for 2008 [155].
Fig. 12. Reasons for hospitalization of individuals with AD: percentage of hospitalized individuals by admitting diagnosis. All hospitalizations for individuals
with a clinical diagnosis of probable or possible AD were used to calculate percentages. The remaining 37% of hospitalizations were due to other reasons.
Created from data from Rudolph et al. [272].
Tab
Av
Me
Alz
He
Inp
Me
Ski
Nu
Ho
Ho
Pre
*
ora
y
ple
sist
NO
cia
Alzheimer’s Association / Alzheimer’s & Dementia 10 (2014) e47-e92e70 Skilled nursing facility: Skilled nursing facilities pro-
vide direct medical care that is performed or super-
vised by registered nurses such as giving intravenous
fluids, changing dressings, and administering tube
feedings [273]. There are 349 skilled nursing facility
stays per 1000 beneficiaries with AD and other
dementias compared with 39 stays per 1000
beneficiaries for peoplewithout these conditions [155].
 Home health care: A total of 23% of Medicare benefi-
ciaries aged 65 years and older with AD and other de-
mentias have at least one home health visit during the
year compared with 10% of Medicare beneficiaries
aged 65 years and older without AD and other demen-
tias [139].le 9
erage annual per-person payments for health-care services provided to
dicare beneficiaries aged 65 years and older with and without
heimer’s disease and other dementias, in 2013 dollars
alth-care service
Beneficiaries with
Alzheimer’s disease
and other dementias
Beneficiaries withou
Alzheimer’s disease
and other dementias
atient hospital $10,748 $4321
dical provider* 6220 4124
lled nursing facility 4072 474
rsing home 18,898 840
spice 1880 184
me health 1507 486
scription medicationsy 2799 2853
“Medical provider” includes physician, other medical provider and lab
tory services, and medical equipment and supplies.
Information on payments for prescription drugs is available only for peo
who were living in the community; that is, not in a nursing home or as
ed living facility.
TE. Created from unpublished data from the Medicare Current Benefi
ry Survey for 2008 [155].t
-
-
-
-6.2.2. Costs of health-care services
With the exception of prescription medications, average
per-person payments for health-care services (hospital,
physician and other medical provider, nursing home, skilled
nursing facility, hospice, and home health care) were higher
for Medicare beneficiaries with AD and other dementias
than for other Medicare beneficiaries in the same age group
(Table 9) [155]. The fact that only payments for prescription
drugs are lower for those with AD and other dementias
underscores the lack of effective treatments available to
those with dementia.
6.2.3. Use and costs of health-care services for individuals
newly diagnosed with AD
Those newly diagnosed with AD have higher health-care
use and costs in the year before diagnosis and in the 2 subse-
quent years than those who do not receive this diagnosis, ac-
cording to a study of Medicare Advantage enrollees (i.e.,
Medicare beneficiaries enrolled in a private Medicare health
insurance plan) [274]. Enrollees with a new diagnosis of
AD had $2472 more in health-care costs (medical and phar-
macy) in the year before diagnosis, $9896 more in costs in
the year after diagnosis, and $6109more in costs in the second
year after diagnosis. Although more work is needed to under-
stand the underlying drivers of increased utilization immedi-
ately before and after receiving a diagnosis of AD, the
additional health-care use may be attributed to treatments re-
lated to the cognitive impairment or coexisting medical con-
ditions and care related to diagnosing the disease.
6.2.4. Impact of coexisting medical conditions on use and
costs of health-care services
Medicare beneficiaries with AD and other dementias are
more likely than those without dementia to have other
Table 10
Specific coexisting medical conditions among Medicare beneficiaries aged
65 years and older with Alzheimer’s disease and other dementias, 2009
Coexisting condition
Percentage of beneficiaries with
Alzheimer’s disease and other
dementias who also had
coexisting medical condition
Coronary artery disease 30
Diabetes 29
Congestive heart failure 22
Chronic kidney disease 17
Chronic obstructive pulmonary disease 17
Stroke 14
Cancer 9
NOTE. Created from unpublished data from the National 20% Sample
Medicare Fee-for-Service Beneficiaries for 2009 [139].
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people with AD and other dementias who have certain
coexisting medical conditions. In 2009, 30% of Medicare
beneficiaries aged 65 years and older with dementia also
had coronary artery disease, 29% also had diabetes, 22%
also had congestive heart failure, 17% also had chronic
kidney disease, and 17% also had COPD [139].
People with AD and other dementias and a serious coex-
isting medical condition (e.g., congestive heart failure) are
more likely to be hospitalized than people with the same co-
existing medical condition but without dementia (Fig. 13)
[139]. Research has demonstrated that Medicare
beneficiaries with AD and other dementias have more
potentially avoidable hospitalizations for diabetes
complications and hypertension, meaning that the
hospitalizations could possibly be prevented through
proactive care management in the outpatient setting [275].
Similarly, Medicare beneficiaries who have AD and other
dementias and a serious coexisting medical condition have
higher average per-person payments for most health-care
services than Medicare beneficiaries who have the same
medical condition without dementia. Table 11 lists the
average per-person Medicare payments for seven specific
medical conditions among beneficiaries who have AD and
other dementias and beneficiaries who do not have dementia
[139]. Medicare beneficiaries with dementia had higher
average per-person payments in all categories except total
Medicare and hospital care payments for individuals with
congestive heart failure.
6.3. Use and costs of long-term care services
An estimated 60% to 70% of older adults with AD and
other dementias live in the community compared with
98% of older adults without AD and other dementias
[155,276]. Of those with dementia who live in the
community, 75% live with someone and the remaining
25% live alone [155]. People with AD and other dementias
generally receive more care from family members and
other unpaid caregivers as their disease progresses. Manypeople with dementia also receive paid services at home;
in adult day centers, assisted living facilities, or nursing
homes; or in more than one of these settings at different
times in the often long course of the disease. Given the
high average costs of these services (adult day services,
$72 per day [276]; assisted living, $43,756 per year [276];
and nursing home care, $83,230–$92,977 per year [276]),
individuals often deplete their income and assets and
eventually qualify for Medicaid. Medicaid is the only
public program that covers the long nursing home stays
that most people with dementia require in the late stages
of their illnesses.6.3.1. Use of long-term care services by setting
Most people with AD and other dementias who live at
home receive unpaid help from family members and friends,
but some also receive paid home- and community-based
services such as personal care and adult day care. A study
of older people who needed help to perform daily activ-
ities—such as dressing, bathing, shopping, and managing
money—found that those who also had cognitive impair-
ment were more than twice as likely as those who did not
have cognitive impairment to receive paid home care
[277]. In addition, those who had cognitive impairment
and received paid services used almost twice as many
hours of care monthly as those who did not have cognitive
impairment [277].
People with AD and other dementias make up a large pro-
portion of all elderly people who receive nonmedical home
care, adult day services, and nursing home care.
 Home care: According to state home care programs in
Connecticut, Florida, and Michigan, more than one-
third (about 37%) of older people who receive primar-
ily nonmedical home care services such as personal
care and homemaker services have cognitive impair-
ment consistent with dementia [278–280].
 Adult day services: At least half of elderly attendees at
adult day centers have dementia [281,282].
 Assisted living: 42% of residents in assisted living fa-
cilities (i.e., housing that includes services to assist
with everyday activities such as medication manage-
ment and meals) had AD and other dementias in
2010 [283].
 Nursing home care: Of all Medicare beneficiaries aged
65 years and older with AD and other dementias, 31%
live in a nursing home [155]. Of all Medicare
beneficiaries residing in a nursing home, 64% have
AD and other dementias [155].
 AD special care units: An AD special care unit is a
dedicated unit in a nursing home that has tailored serv-
ices for individuals with AD and other dementias.
Nursing homes had a total of 75,876 beds in AD special
care units in 2013, a decrease of 4% compared with the
previous year [284]. These AD special care unit beds
accounted for 72% of all special care unit beds and
Fig. 13. Hospital stays per 1000 beneficiaries aged 65 years or older with specified coexisting medical conditions, with and without AD and other dementias,
2009. Created from unpublished data from the National 20% Sample Medicare Fee-for-Service Beneficiaries for 2009 [139].
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largest percentage of AD special care unit beds as a
proportion of total beds (13.3%), whereas Tennessee
has the smallest percentage of AD special care unit
beds (0.3%; Table 12).
Recent research demonstrates that individuals with de-
mentia often move between a nursing facility, hospital,
and home rather than remaining in a nursing facility [285].
In a longitudinal study of primary care patients with
dementia, researchers found that those discharged from a
nursing facility were nearly equally as likely to be
discharged home (39%) as discharged to a hospital (44%).
Additionally, 74% of individuals admitted to a nursing
facility came directly from a hospital. Individuals with
dementia may also transition between a nursing facility
and hospital or between a nursing facility, home, and
hospital, creating challenges for caregivers and providers
to ensure that care is coordinated across settings. Other
research has shown that nursing home residents frequently
have burdensome transitions at the end of life, including
admission to an intensive care unit in the last month of
life, late enrollment in hospice, and receipt of a feeding
tube [286]. Care coordination for nursing home residents
with advanced cognitive impairment, as measured by the
number of care transitions, varies substantially across
geographic regions of the United States [287]. Researchers
also found that both the number of transitions between
health-care settings and the odds of having a feeding tube
inserted at the end of life varied across the country. Further-
more, individuals with frequent transitions between health-
care settings were more likely to have feeding tubes at theend of life, although feeding tube placement has little or
no benefit.
Research has also demonstrated a decrease in the propor-
tion of individuals with ADwho die in an acute care hospital,
with end-of-life care shifting to home and nursing homes
[288]. Additionally, more than twice as many individuals
with the disease were receiving hospice care at the time of
death in 2009 compared with 2000 (19.5% in 2000 vs.
48.3% in 2009).
Demand for nursing home services and services from
long-term care hospitals is increasing. Long-term care hos-
pitals serve individuals whose acute medical conditions re-
quire long-term care. Individuals are often transferred from
the intensive care units of acute care hospitals to long-term
care hospitals for medical care related to rehabilitation
services, respiratory therapy, and pain management. De-
spite this increasing demand, there have been a number of
restrictions on adding facilities and increasing the number
of beds in existing facilities. In addition, the Medicare,
Medicaid, and State Children’s Health Insurance Program
Extension Act of 2007 issued a 3-year moratorium on
both the designation of new long-term care hospitals and in-
creases in Medicare-certified beds for existing long-term
care hospitals [289]. This moratorium was in response to
the need for Medicare to develop criteria for admitting
beneficiaries to long-term care hospitals, where stays aver-
age more than 25 days [290]. The moratorium expired in
late 2012 [289,291]. In 2011, certificate-of-need programs
were in place in 37 states to regulate the number of nursing
home beds, and a number of these states had implemented a
certificate-of-need moratorium to prevent growth in the
number of beds and/or facilities [292].
Table 11
Average annual per-person payments by the type of service and coexisting medical condition for Medicare beneficiaries aged 65 years and older, with and
without Alzheimer’s disease and other dementias, 2009, in 2013 dollars*
Medical condition by Alzheimer’s
disease/dementia (AD/D) status
Average per-person Medicare payment
Total Medicare payments Hospital care Physician care
Skilled nursing
facility care Home health care Hospice care
Coronary artery disease
With AD/D $27,033 $9769 $1701 $4309 $2721 $2348
Without AD/D 16,768 7020 1301 1160 1171 342
Diabetes
With AD/D 26,381 9296 1593 4177 2803 2121
Without AD/D 14,581 5730 1121 1193 1111 240
Congestive heart failure
With AD/D 25,907 11,095 1756 4777 2848 2944
Without AD/D 29,756 11,359 1755 2589 2244 833
Chronic kidney disease
With AD/D 31,892 12,246 1884 4807 2659 2560
Without AD/D 24,538 10,264 1649 1983 1646 530
Chronic obstructive pulmonary disease
With AD/D 29,326 10,914 1793 4709 2821 2651
Without AD/D 20,072 8554 1474 1716 1516 665
Stroke
With AD/D 27,517 9625 1653 4521 2578 2759
Without AD/D 19,755 7461 1405 2317 1891 652
Cancer
With AD/D 25,322 8653 1552 3624 2221 2890
Without AD/D 16,572 5871 1190 981 788 593
*This table does not include payments for all kinds of Medicare services, and as a result, the average per-person payments for specific Medicare services do
not sum up to the total per-person Medicare payments.
NOTE. Created from unpublished data from the National 20% Sample Medicare Fee for Service Beneficiaries for 2009 [139].
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Costs are high for care provided at home or in an adult
day center, assisted living facility, or nursing home. The fol-
lowing estimates are for all users of these services. The only
exception is the cost of AD special care units in nursing
homes, which only applies to people with AD and other de-
mentias.
 Home care: In 2012, the average cost for a paid non-
medical home health aide was $21/h or $168 for an
8-hour day [276].
 Adult day centers: In 2012, the average cost of adult
day services was $72/d. Ninety-five percent of adult
day centers provided care for people with AD and other
dementias, and 2% of these centers charged an addi-
tional fee for these clients [276].
 Assisted living facilities: In 2012, the average cost for
basic services in an assisted living facility was $3646/
mo, or $43,756/y. Seventy-two percent of assisted living
facilities provided care to people with AD and other de-
mentias, and 52% had a specific unit for peoplewith AD
and other dementias. In facilities that charged a different
rate for individuals with dementia, the average rate was
$4937/mo, or $59,250/y, for this care [276].
 Nursing homes: In 2012, the average cost for a private
room in a nursing home was $255/d or $92,977/y. The
average cost of a semiprivate room in a nursing home
was $228/d or $83,230/y. Approximately 80% of nurs-
ing homes that provide care for people with AD chargethe same rate for those with AD as they do for those
without the disease. In the few nursing homes that
charged a different rate, the average cost for a private
room for an individual with AD was $13 higher
($268/d or $97,820/y), and the average cost for a semi-
private room was $8 higher ($236/d or $86,140/y)
[276]. Fifty-five percent of nursing homes that provide
care for people with AD and other dementias had sep-
arate AD special care units [276].
6.3.3. Affordability of long-term care services
Few individuals with AD and other dementias have suffi-
cient long-term care insurance or can afford to pay out of
pocket for long-term care services for as long as the services
are needed.
 Income and asset data are not available for people with
AD and other dementias specifically, but 50% of Med-
icare beneficiaries had incomes of $22,604 or less, and
25% had incomes of $13,616 or less in 2010 [293,294].
 Fifty percent of Medicare beneficiaries had retirement
accounts of $2236 or less, 50% had financial assets of
$32,319 or less, and 50% had total savings of $56,224
or less, equivalent to less than 1 year of nursing home
care in 2010 [294].
6.3.4. Long-term care insurance
In 2010, about 7.3 million people had long-term care in-
surance policies [295]. Private health and long-term care
Table 12
Total nursing home beds and Alzheimer’s disease special care unit beds by
state, 2013
State Total beds
Alzheimer’s
disease special
care unit beds
Alzheimer’s
disease beds as
a percentage of
total beds
Alabama 26,685 1245 4.7
Alaska 778 37 4.8
Arizona 16,668 887 5.3
Arkansas 24,527 321 1.3
California 121,356 2984 2.5
Colorado 20,462 2078 10.2
Connecticut 27,837 1691 6.1
Delaware 4986 375 7.5
District of Columbia 2766 70 2.5
Florida 83,145 3880 4.7
Georgia 39,817 1455 3.7
Hawaii 4260 106 2.5
Idaho 5842 226 3.9
Illinois 99,196 4835 4.9
Indiana 59,480 6166 10.4
Iowa 34,831 1672 4.8
Kansas 25,643 422 1.6
Kentucky 26,161 541 2.1
Louisiana 35,592 1652 4.6
Maine 7020 640 9.1
Maryland 28,536 884 3.1
Massachusetts 48,640 3874 8.0
Michigan 47,007 1039 2.2
Minnesota 30,526 2512 8.2
Mississippi 18,576 229 1.2
Missouri 55,138 4487 8.1
Montana 6713 542 8.1
Nebraska 15,936 1278 8.0
Nevada 5979 278 4.6
New Hampshire 7513 592 7.9
New Jersey 52,281 1008 1.9
New Mexico 6716 510 7.6
New York 116,849 3903 3.3
North Carolina 44,549 1608 3.6
North Dakota 6151 454 7.4
Ohio 91,785 3630 4.0
Oklahoma 29,296 758 2.6
Oregon 12,267 259 2.1
Pennsylvania 88,200 6351 7.2
Rhode Island 8715 1162 13.3
South Carolina 19,721 89 0.5
South Dakota 6903 552 8.0
Tennessee 37,234 124 0.3
Texas 135,066 2462 1.8
Utah 8464 590 7.0
Vermont 3199 195 6.1
Virginia 32,667 1254 3.8
Washington 21,654 864 4.0
West Virginia 10,888 137 1.3
Wisconsin 34,960 2663 7.6
Wyoming 2984 305 10.2
United States 1,702,165 75,876 4.4
NOTE. Created from data from the American Health Care Association
[284].
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care spending in 2009, representing $19 billion of the
$271 billion in long-term care spending [296]. The privatelong-term care insurance market has decreased substantially
since 2010, however, with five major insurance carriers ei-
ther exiting the market or substantially increasing premiums,
making policies unaffordable for many individuals [297].
6.3.5. Medicaid costs
Medicaid covers nursing home care and long-term care
services in the community for individuals whomeet program
requirements for level of care, income, and assets. To receive
coverage, beneficiaries must have low incomes. Most nurs-
ing home residents who qualify for Medicaid must spend
all their Social Security income and any other monthly in-
come, except for a very small personal needs allowance, to
pay for nursing home care. Medicaid only makes up the dif-
ference if the nursing home resident cannot pay the full cost
of care or has a financially dependent spouse.
The federal and state governments share in managing and
funding the program, and states differ greatly in the services
covered by their Medicaid programs. Medicaid plays a crit-
ical role for people with dementia who can no longer afford
to pay for long-term care expenses on their own. In 2008,
58% of Medicaid spending on long-term care was allocated
to institutional care, and the remaining 42% was allocated to
home- and community-based services [296].
Total Medicaid spending for people with AD and other
dementias is projected to be $37 billion in 2014 (in 2014 dol-
lars).A21 Total per-person Medicaid payments for Medicare
beneficiaries aged 65 years and older with AD and other de-
mentias were 19 times as great as Medicaid payments for
other Medicare beneficiaries. Much of the difference in pay-
ments for beneficiaries with AD and other dementias is due
to the costs associated with long-term care (nursing homes
and other residential care facilities such as assisted living fa-
cilities) and the greater percentage of people with dementia
who are eligible for Medicaid. Medicaid paid an average of
$25,494 per person for Medicare beneficiaries with AD and
other dementias living in a long-term care facility compared
with $237 for those with the diagnosis living in the commun-
ity and an average of $561 for older adults without the diag-
nosis living in the community and long-term care facilities
(Table 8) [155].
In a study of Medicaid beneficiaries with a diagnosis of
AD, researchers found significant differences in the cost of
care by race/ethnicity. These results demonstrated that non-
Hispanic blacks had significantly higher cost of care than
whites or Hispanics, primarily due to more inpatient care
and greater severity of illness. These differences may be at-
tributable to delays in accessing timely primary care, lack
of care coordination, and duplication of services across
providers. However, more research is needed to understand
the reasons for this health-care disparity [298].6.4. Use and costs of hospice care
Hospices provide medical care, pain management, and
emotional and spiritual support for people who are dying,
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also provide emotional and spiritual support and bereave-
ment services for families of people who are dying. The
main purpose of hospice care is to allow individuals to die
with dignity and without pain and other distressing symp-
toms that often accompany terminal illness. Individuals
can receive hospice care in their homes, assisted living res-
idences, or nursing homes. Medicare is the primary source
of payment for hospice care, but private insurance, Medic-
aid, and other sources also pay for hospice care.
In 2009, 6% of people admitted to hospices in the United
States had a primary hospice diagnosis of AD (61,146 peo-
ple) [299]. An additional 11% of those admitted to hospices
in the United States had a primary hospice diagnosis of non-
AD dementia (119,872 people) [299]. Hospice length of stay
has increased over the past decade. The average length of
stay for hospice beneficiaries with a primary hospice
diagnosis of AD increased from 67 days in 1998 to
106 days in 2009 [299]. The average length of stay for
hospice beneficiaries with a primary diagnosis of non-AD
dementia increased from 57 days in 1998 to 92 days in
2009 [299]. Average per-person hospice care payments for
beneficiaries with AD and other dementias were 10 times
as great as for all other Medicare beneficiaries ($1880 per
person compared with $184 per person) [155].6.5. Projections for the future
Total annual payments for health care, long-term care,
and hospice care for people with AD and other dementias
are projected to increase from $214 billion in 2014 to $1.2
trillion in 2050 (in 2014 dollars). This dramatic rise includes
a sixfold increase in government spending under Medicare
and Medicaid and a fivefold increase in out-of-pocket spen-
ding.A217. Special report: Women and AD
In 2010, the Alzheimer’s Association conducted a
groundbreaking poll with the goal of exploring the compel-
ling connection between AD and women. Data from that poll
were published in The Shriver Report: A Woman’s Nation
Takes on Alzheimer’s [300], which also included essays
and reflections that gave personal perspectives to the poll’s
numbers. That report revealed not only the striking impact
of the disease on individual lives, but also its especially
strong effects on women—women living with the disease,
as well as women who are caregivers, relatives, friends,
and loved ones of those directly affected.
Inspired by compelling findings published in The Shriver
Report, the Alzheimer’s Association conducted a follow-up
poll in 2014A17 to continue exploring how AD affects the
lives of Americans. This special report reveals results of
this new poll with a focus on women, and it discusses recent
research discoveries on AD and gender.7.1. Incidence and prevalence
As discussed in the Prevalence section, almost two-thirds
of Americans with AD are women. The prevailing view as to
why women account for such a high percentage of existing
cases is that, on average, women have longer life spans
than men and are thereby more likely to reach an age of
high risk for AD. As noted in the Prevalence section, there
is no evidence that women are more likely than men to de-
velop dementia at any given age. Nevertheless, various ex-
planations have been proposed to explain the differing
prevalence of AD between women and men.
Earlier in the report, incidence data from the Framingham
Study are presented showing that, at the age of 65 years,
women have a higher lifetime risk of AD than men. Another
type of analysis from the Framingham Study was published
very recently; the goal of that analysis was to explore how
the incidence of AD or dementia was affected by other
causes of death in people between ages of 45 and 65 years
[301]. The study confirmed that men have a higher rate of
death from cardiovascular disease than women in that age
range. Furthermore, because a high risk of cardiovascular
disease is also associated with a high risk of AD, the
researchers concluded that the death of men from
cardiovascular disease between ages 45 and 65 was
reducing the pool of men at high risk for AD at later ages.
They estimated that this effect explained 20% to 50% of
the difference in incidence of AD among men and women
older than 65 years.
Other possible explanations for the higher incidence and
prevalence of AD among women have been proposed
[301,302], but definitive scientific evidence is sparse.
There are well-established differences in brain structure be-
tween men and women, some of which may be associated
with an increased risk of cognitive decline or dementia. Fur-
thermore, women and men exhibit different forms of behav-
ioral changes associated with the disease [303], possibly
suggesting that the disease affects male and female brains
in different ways. This concept is supported by recent
evidence from imaging studies suggesting that the disease
causes structural changes in the brain that differ between
men and women [304].
Women and men also have different hormonal physiol-
ogy, and sex-specific hormones are known to have effects
on the brain. There are also differences in the molecular
characteristics of cells in women and men, including ge-
netic differences. Several genetic variants have been shown
to be associated with an increased risk of AD, including the
34 variant of the APOE gene. This gene variant is the stron-
gest genetic risk factor yet identified for late-onset AD. In-
creasing evidence suggests that the higher risk for AD
associated with APOE 34 is more pronounced in women
than men [305].
Several studies have found brain changes associated with
AD or MCI that differ between men and women, including a
recent study using brain imaging in which specific brain
Fig. 14. Responses of Americans aged 60 years or older when asked which condition they were most afraid of getting. Created from data from the YouGov
survey.A25
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[306]. At this time, however, much more research is
needed to define biological differences in the disease
process between women and men.7.2. Knowledge and attitudes about AD and dementia
The 2014 Alzheimer’s Association Women and Alz-
heimer’s PollA17 questioned 3102 American adults about
their attitudes, knowledge, and experiences related to AD
and dementia. Adults identified as informal caregivers
were asked additional questions about their caregiving expe-
riences (see section 7.3 on Caregiving).
Fifty-six percent of all respondents reported knowing
someone with the disease. Those who knew someone with
the disease were also more likely to have heard or read about
the disease than those who did not know someone with the
disease.
As discussed in the Overview, heredity (family history) is
only one of many risk factors for AD, and many cases occur
in people with little or no family history. However, 24% of
poll respondents agreed with the erroneous statement that
AD must run in their family for them to be at risk. The rates
of agreement were similar among women and men, but there
were large differences across ethnic groups. Among people
who self-identified as Latino or Asian, 33% and 45%, re-
spectively, agreed with this statement. These findings reveal
a need for additional education about risk factors for AD
across all sectors of the population and an even greater
need in certain ethnic groups.
Women showed higher levels of concern than men that
they or someone in their immediate family would get AD
or dementia, with 56% of women and 44% of men saying
they were “very concerned” about that possibility. Whenasked if the idea of getting AD “frightened” them, 58% of
women said yes compared with 43% of men. These findings
are consistent with a recent surveyA25 of people aged 60
years and older conducted by YouGov, which found that
AD or dementia was more feared than other chronic condi-
tions, including cancer, heart disease, and stroke (Fig. 14).
The 2014 Alzheimer’s Association poll also asked re-
spondents about the aspects of AD that frightened them
most. The five most common answers are shown in Fig. 15
(multiple responses were allowed). Overall, women and
men gave similar responses to this question.
Concern or fear about the possibility of getting AD may
have psychological or behavioral consequences, but those
consequences are not well understood, and more research
into this issue has been recommended [302]. Excessive fear
or concern about developing a chronic condition can be
associated with unproductive anxiety, chronic stress, and ill-
advised behaviors, such as seeking unnecessary testing or
treatment or attempting to ward off the disease by using un-
proven and potentially dangerous “remedies.” On the other
hand, some degree of concernmay be beneficial as it may pro-
mote better education, appropriate screening, and healthful
behaviors such as physical activity and a healthy diet.
In the 2014 Alzheimer’s Association poll, 26% of women
had thought about what care options might be available to
them if they were to get AD or dementia. Only 19% of
men had thought about potential care options. Caregivers
of someone with AD or dementia, and especially women
caregivers, were much more likely to have thought about po-
tential care options (women, 48%, and men, 25%).
When asked about the care options they would prefer if
they were to get AD or dementia, women and men gave sim-
ilar responses. About 36%would prefer to be taken care of at
home by a spouse or children, and nearly the same
Fig. 15. Why does the possibility of getting AD frighten you? Created from data from the 2014 Alzheimer’s Association Women and Alzheimer’s Poll.A17
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ing home that specializes in AD care. Fewer (20%) stated
that they would want to receive care in their own home
from a paid caregiver.7.3. Caregiving
In the 2014 Alzheimer’s Association poll, 512 peopleA26
identified themselves as providing the majority of care for
someone (not living in a residential care facility) with AD
or dementia or equally sharing those responsibilities with an-
other person. Of these informal caregivers, 63% were
women, consistent with The Shriver Report and other studies
that have found that women constitute about 60% to 70% of
all informal caregivers for seniors [177,178,184,
300,307,308]. Because many people do not report the care
of an ailing spouse as caregiving and because it is more
common for a wife to be caring for an ailing husband than
the converse, women may account for even more informal
caregiving than these studies suggest [307].
Many factors influence how, why, and when a person be-
comes a caregiver for someone with AD or dementia. In the
2014 Alzheimer’s Association poll, 37% of caregivers
agreed with the statement, “I had no choice in becoming a
caregiver.” A higher percentage of female caregivers agreed
with that statement (39%) than male caregivers (33%), con-
sistent with previous studies [184,300]. These findings have
important implications for the caregiver’s experience and the
perceived burden of caregiving. For example, caregivers
who believed they had no choice in accepting the
caregiving role, or who felt captured by that role,
perceived the emotional stress and burden of caregiving to
be significantly higher than caregivers who felt they had a
choice [309,310]. Research indicates that women who
anticipated becoming caregivers for their aging parentswere better able to adapt to their caregiving role than those
who become caregivers unexpectedly [311].
Like the 2010 poll, the 2014 Alzheimer’s Association poll
explored other factors that influenced why respondents be-
came caregivers for someone with AD or dementia. The re-
sults of the 2014 poll are shown in Fig. 16 and are similar to
the results from the 2010 poll. In both polls, the factors most
frequently cited has having “a lot” of importance were the
desire to keep the care recipient in their home and the
proximity of the caregiver to the care recipient. Women and
men shared many values regarding the factors affecting their
decisions to become caregivers. The factors with the largest
differences were desire to keep the care recipient in their
home, cost of in-home help, insurance coverage, and guilt.
In the 2014 Alzheimer’s Association poll, informal care-
givers were asked about the number of hours they spent
each week performing caregiving duties. About half of all
caregivers spent 20 hours or less each week performing those
duties. However, there is a distinct group of caregivers who
live with the care recipient and are “on duty” as caregivers
24 hours a day, 7 days a week. They account for about 23%
of all caregivers. These full-time caregivers are much more
likely to be women than men. Fig. 17 shows ratios of female
to male caregivers in different categories according to the
amount of time spent in caregiving activities each week.
Among caregivers reporting less than 10 h/wk of caregiving
activity, the ratio of women to men was 1.1:1, indicating
that there were 1.1 female caregivers for every male
caregiver in that category. As the amount of time dedicated
to caregiving activity increased, the ratio of female to male
caregivers increased in a marked and stepwise manner.
Among caregivers spending 21 to more than 60 h/wk, there
were more than 2 women for every man. Among caregivers
who live with the care recipient and are on duty 24 hours a
day, there were 2.5 women for every man.
Fig. 16. Factors cited by caregivers as having “a lot” of influence on their decision to assume caregiving responsibilities. Created from data from the 2014
Alzheimer’s Association Women and Alzheimer’s Poll.A17
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a 2008 Canadian poll, a 2009 NAC/AARP poll, and
the 2010 Alzheimer’s Association poll [178,300,307].
Considered together, these studies support the
conclusion that women are substantially more likely
than men to assume intensive time-consuming caregiving
roles such as those in which the care recipient lives in the
caregiver’s household and requires around-the-clock
care.
7.3.1. Caregiver burden
As discussed in the Caregiving section (5.1.7.), providing
informal care for someone with AD or dementia can be aheavy burden, straining finances, employment, family rela-
tionships, and the caregiver’s own health and well-being.
Some older studies have found that those strains are even
more severe when the caregiver lives with the care recipient
and is on duty 24 hours a day [312]. As shown in Fig. 18, the
percentage of female caregivers reporting stresses and
strains associated with caregiving are substantially higher
among full-time caregivers than among those providing
care for 20 h/wk or less.
Although full-time caregivers carried a much heavier bur-
den than those providing care for less than 20 h/wk, the bur-
den carried by the latter group was still quite heavy, with the
potential to cause significant disruption in life. For example,
Fig. 17. Ratios of the number of female to male caregivers according to the
amount of time spent caregiving each week. Created from data from the
2014 Alzheimer’s Association Women and Alzheimer’s Poll.A17
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week, 24% reported that it led to marital strain or was emo-
tionally stressful. Nearly as many reported strains on finan-
ces and family relationships.
Studies have consistently found that the burden of care-
giving is felt more strongly by women than men, and the
2014 poll reaffirms those findings.
 Forty-seven percent of women and 24% of men consid-
ered their caregiving role to be physically stressful (de-
fined as 4 or 5 on a scale of 1–5, with 5 being “very
stressful”).
 Sixty-two percent of women and 52% of men consid-
ered their caregiving role to be emotionally stressful.
 About 30% of caregivers reported feeling isolated in
their caregiving roles, and this rate was similar among
men and women. But among those who reported feel-
ing isolated, women were much more likely than men
to link isolation with feeling depressed (17% compared
with 2%).
 Women were also more likely than men to report mar-
ital strain and spending less time with their spouse as
consequences of caregiving.
 Among those caregivers who were employed when
they started caregiving, women were more likely
than men to experience several adverse consequences
related to employment. The consequences showing
the greatest difference between men and women are
shown in Fig. 19. Nearly seven times as many
women as men went from working full-time to work-
ing part-time while being a caregiver, and more than
twice as many women as men reported having to
give up work entirely or to have lost job benefits.
7.3.2. Sources of caregiving burden
Several explanations have been offered as to why the bur-
den of caregiving is heavier on women than men, and it is
likely that several factors contribute. One factor has alreadybeen discussed: women are more likely than men to be car-
ing for a loved one who lives in their household and to be on
duty 24 hours a day.
Another contributing factor may be differences in care-
giving duties assumed by women and men. In at least two
previous polls of caregivers, female caregivers were substan-
tially more likely than male caregivers to help the care recip-
ient with personal aspects of care such as bathing, dressing,
toileting, and managing incontinence [300,307]. At least one
other study reached similar conclusions [313].
Another study of caregivers for elderly people found that
women were more likely than men to perform caregiving
tasks requiring a regular schedule, possibly adding to the
burden of caregiving and competing with other responsibil-
ities such as employment [307]. This aspect of caregiving
may be related to responses to a question in the 2014
Alzheimer’s Association poll asking caregivers assisting
someone outside of their household how often they visited
that person. Thirty-seven percent of female caregivers an-
swered that they visited every day, whereas only 25% of
male caregivers visited every day.
Another factor contributing to the burden of caregiving is
the availability of other caregivers and sources of support. In
the 2014 Alzheimer’s Association poll, slightly fewer female
caregivers (56%) than male caregivers (60%) reported that
another person provided caregiving help to the care recipi-
ent. Conversely, 56% of female caregivers and 47% of
male caregivers reported seeking additional caregiving re-
sources. Other studies have also found that female caregivers
received less caregiving support than male caregivers
[307,314,315]. Even women caring for husbands with
advanced AD or near the end of life received less support
from family and friends than men caring for wives in
similar situations [313,316].
Another difference between female and male caregivers
found in the 2014 Alzheimer’s Association poll, as well as
the 2009 NAC/AARP poll, was that women, on average,
had been providing informal caregiving for longer than
men. In the 2014 poll, 35% of female caregivers and 26%
of male caregivers had been providing care for more than
5 years. Among caregivers reporting that they had been pro-
viding care for less than a year (Fig. 20), the ratio of female
to male caregivers was 1.2:1 (for every male caregiver, there
were 1.2 female caregivers). As the duration of caregiving
increased, the ratio of female to male caregivers also
increased, to 1.5 (1–3 years), 1.7 (4–5 years), and 2.3
(more than 5 years). These results suggest that women are
more likely than men to continue caregiving for prolonged
durations.
Several studies have found that the burden of caregiving is
dependent not only on the gender of the caregiver [310] but
also on the gender of the care recipient [317]. Furthermore,
caregiver burden is substantially higher when the care
recipient exhibits behavioral problems [177,310,318]. A
recent study comparing the experiences of men and women
caring for spouses with dementia confirmed earlier studies
Fig. 18. Burdens of caregiving among women providing around-the-clock informal care or 20 hours or less of informal care for someone with AD or dementia.
*A “great deal” or “good amount” of strain reported. **Responded “yes” when questioned whether caregiving was causing marital strain. ***Responded 5
(very stressful) when asked to rate stress on a scale of 1 to 5. Created from data from the 2014 Alzheimer’s Association Women and Alzheimer’s Poll.A17
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behavioral problems than women with dementia [315]. As a
consequence, women caring for a husband with dementia
were more likely to experience a high burden because of
behavioral problems than men caring for a wife. In the 2014
Alzheimer’s Association poll, 16% of caregivers were
caring for a spouse, and the situation in which a wife was
caring for a husband with dementia was about twice as
common as a husband caring for a wife with dementia.7.4. Paid personal care and home health aides
Personal care aides assist older people or others with
ADLs, either in the care recipient’s home or in a care fa-Fig. 19. Consequences of caregiving on aspects of employment among female and
Women and Alzheimer’s Poll.A17cility. Home health aides work in the care recipient’s
home and may assist with health care and personal care
such as bathing, dressing, and grooming. Personal care
and home health aides provide valuable services for people
with AD or dementia, allowing many to stay in their own
homes. They also provide support and respite to family,
friends, and other informal caregivers and perform services
that some informal caregivers are unable to perform. For
many people with AD or dementia, a personal care aide
or home health aide is the only personal contact they expe-
rience on a daily basis.
According to the US Department of Labor, women ac-
count for about 85% of all personal care aides and home
health aides [319]. Despite the fact that these occupationsmale caregivers. Created from data from the 2014 Alzheimer’s Association
Fig. 20. Ratio of female tomale caregivers according to duration of caregiv
ing. Created from data from the 2014 Alzheimer’s Association Women and
Alzheimer’s Poll.A17
Alzheimer’s Association / Alzheimer’s & Dementia 10 (2014) e47-e92 e81-are among the fastest growing occupations with the highest
demand for workers in the United States, the average wage
for such workers was only slightly above $10/h in 2012
[320,321]. Average annual wages for personal care aides
and home health aides were below $22,000 in 2012, only
51% of the national average of $42,700 for all workers.
Surprisingly, even these professions exhibit a gender pay
gap; in 2012, the median weekly earnings of male personal
care aides were about 13% higher than earnings of female
personal care aides [319].7.5. Conclusions
Results of the 2014 Alzheimer’s Association Women and
Alzheimer’s Poll provide yet more evidence that AD takes a
stronger toll on women thanmen.Morewomen than men de-
velop the disease, and women are more likely than men to be
informal caregivers for someone with AD or dementia.
Results from the 2014 poll also reveal that as caregiving re-
sponsibilities become more time-consuming and burden-
some or extend for prolonged durations, women assume an
even greater share of the caregiving burden. In addition,
women are less likely than men to receive outside help for
caregiving. The higher caregiving burden placed on women
has many consequences, including higher emotional and
physical stress, strained family relationships, and lost em-
ployment opportunities.Acknowledgments
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A1Number of Americans aged 65 years and older with AD
for 2014 (prevalence of AD in 2014): The number 5 million
is from published prevalence estimates based on incidence
data from the CHAP and population estimates from the
2010 US Census [114].
A2Proportion of Americans aged 65 years and older with
AD: The 11% is calculated by dividing the estimated number
of people aged 65 years and older with AD (5 million) by the
US population aged 65 years and older in 2014, as projected
by the US Census Bureau (44.7 million)5 11%. Eleven per-
cent is the same as one in nine.
A3Percentage of total AD cases by age groups: Percen-
tages for each age group are based on the estimated
200,000 under 65 years, plus the estimated numbers (in mil-
lions) for people aged 65 to 74 (0.8), 75 to 84 (2.3), and 851
years (2.0) based on prevalence estimates for each age group
and incidence data from the CHAP [114].
A4Differences between CHAP and ADAMS estimates for
AD prevalence: ADAMS estimates the prevalence of AD to
be lower than does the CHAP, at 2.3 million Americans
aged 71 years and older in 2002 [116]. (Note that CHAP
estimates referred to in this end note are from an earlier
study using 2000 US Census data [144]) At a 2009
conference convened by the NIA and the Alzheimer’s
Association, researchers determined that this discrepancy
was mainly due to two differences in diagnostic criteria: (1)
a diagnosis of dementia in ADAMS required impairments
in daily functioning and (2) people determined to have
vascular dementia in ADAMS were not also counted as
having AD, even if they exhibited clinical symptoms of AD
[117]. Because the more stringent threshold for dementia in
ADAMS may miss people with mild AD and because
clinicopathologic studies have shown that mixed dementia
Alzheimer’s Association / Alzheimer’s & Dementia 10 (2014) e47-e92e90due to both AD and vascular pathology in the brain is very
common [4], the Association believes that the larger CHAP
estimates may be a more relevant estimate of the burden of
AD in the United States.
A5Number of women and men aged 65 years and older
with AD in the United States: The estimates for the number
of US women (3.2 million) and men (1.8 million) aged 65
years and older with AD in 2013 is from unpublished data
from the CHAP. For analytical methods, see Hebert et al.
[114].
A6 Prevalence of AD and other dementias in older whites,
African-Americans, and Hispanics: The statement that
African-Americans are twice as likely and Hispanics 1.5
times as likely as whites to have Alzheimer’s disease and
other dementias is the conclusion of an expert review of a
number of multiracial and multiethnic data sources, as re-
ported in detail in the Special Report of 2010 Alzheimer’s
Disease Facts and Figures.
A7Number of new cases of AD this year (incidence of AD
in 2014): The CHAP study estimated that there would be
454,000 new cases in 2010 and 491,000 new cases in 2020
[140]. The Alzheimer’s Association calculated that the
incidence of new cases in 2014 would be 461,400 by
multiplying the 10-year change from 454,000 to 491,000
(37,000) by 0.4 (for the number of years from 2010 to
2014 divided by the number of years from 2010 to 2020),
adding that result (14,800) to the Hebert et al. [140]
estimate for 2010 (454,000) 5 468,800. Rounded to the
nearest thousand, this is 469,000 new cases of AD in 2014.
The same technique for linear extrapolation from 2000 to
2010 projections was used to calculate the number of new
cases in 2014 for ages 65 to 74, 75 to 84, and 85 years and
older. The increases in number of new cases of AD from
year to year appears to be mostly due to changes in
demographics rather than changes in the underlying
incidence rate for AD, which in a recent analysis was
shown to remain stable over a decade [322]. The age
group–specific AD incident rate is the number of new
people with AD per population at risk (the total number of
people in the age group in question). These incidence rates
are expressed as number of new cases per 1000 people. The
total number of people per age group for 2014 was obtained
from population projections from the 2000 US Census (see
2000 National Population Projections: Summary Tables
located at http://www.census.gov/population/projections/
files/natproj/summary/np-t3-d.pdf).
A8Number of seconds for the development of a new case of
AD: Although AD does not present suddenly like stroke or
heart attack, the rate at which new cases occur can be com-
puted in a similar way. The 67 seconds number is calculated
by dividing the number of seconds in a year (31,536,000) by
the number of new cases in a year.A7 The number of seconds
in a year (31,536,000) divided by 468,800 5 67.3 seconds,
rounded to 67 seconds. Using the same method of calcula-
tion for 2050, 31,536,000 divided by 959,000 (from Hebert
et al [140]) 5 32.8 seconds, rounded to 33 seconds.A9Criteria for identifying subjects with AD and other de-
mentias in the Framingham Study: Starting in 1975, nearly
2800 people from the Framingham Study who were aged
65 years and free of dementia were followed for up to
29 years. Standard diagnostic criteria (DSM-IV criteria)
were used to diagnose dementia in the Framingham Study,
but, in addition, the subjects had to have at least “moderate”
dementia according to the Framingham Study criteria, which
is equivalent to a score of 1 or more on the Clinical Dementia
Rating scale, and they had to have symptoms for 6 months or
more. Standard diagnostic criteria (the NINCDS–ADRDA
criteria from 1984) were used to diagnose AD. The examina-
tion for dementia and AD is described in detail in Seshadri et
al. [123].
A10State-by-state prevalence of AD: These state-by-state
prevalence numbers are based on an unpublished analysis
of incidence data from the CHAP, projected to each state’s
population, with adjustments for state-specific age, gender,
years of education, race, and mortality provided to the Alz-
heimer’s Association in 2013 by a team led by Liesi Hebert,
Sc.D., from Rush University Institute on Healthy Aging.
A11Projected number of people with AD: This comes from
the CHAP study [114]. Other projections are somewhat
lower (e.g., Brookmeyer et al [323]) because they relied on
more conservative methods for counting people who
currently have AD.A4 Nonetheless, these estimates are
statistically consistent with each other, and all projections
suggest substantial growth in the number of people with
AD over the coming decades.
A12Projected number of people aged 65 years and older
with AD in 2025: The number 7.1 million is based on a linear
extrapolation from the projections of prevalence of AD for
the years 2020 (5.8 million) and 2030 (8.4 million) from
CHAP [114].
A13Previous high and low projections of AD prevalence in
2050: High and low prevalence projections for 2050 from the
U.S. Census were not available for the most recent analysis
of CHAP data. The previous high and low projections indi-
cate that the projected number of Americans with AD in
2050 aged 65 years and older will range from 11 to 16 mil-
lion [144].
A14Deaths with AD: The estimates for the number of
Americans dying with AD, 600,000 in 2010 and 700,000
in 2014, come from Weuve et al [153]. Please note that the
figures reported in 2013 Alzheimer’s Disease Facts and
Figures were erroneously too low due to a summing error.
A15Annual mortality rate due to AD by state: Unadjusted
death rates are presented rather than age-adjusted death
rates to provide a clearer depiction of the true burden of
mortality for each state. States such as Florida with larger
populations of older people will have a larger burden of
mortality due to AD.
A16Number of family and other unpaid caregivers of peo-
ple with AD and other dementias: To calculate this number,
the Alzheimer’s Association started with data from the
BRFSS. In 2009, the BRFSS survey asked respondents
Alzheimer’s Association / Alzheimer’s & Dementia 10 (2014) e47-e92 e91aged 18 years and older whether they had provided any reg-
ular care or assistance during the past month to a family
member or friend who had a health problem, long-term ill-
ness, or disability. To determine the number of family and
other unpaid caregivers nationally and by state, we applied
the proportion of caregivers nationally and for each state
from the 2009 BRFSS (as provided by the CDC, Healthy
Aging Program, unpublished data) to the number of people
aged 18 years and older nationally and in each state from
the US Census Bureau report for July 2013. Available at
www.census.gov/popest/data/datasets.html. Accessed on
January 6, 2014. To calculate the proportion of family and
other unpaid caregivers who provide care for a person with
AD or another dementia, the Alzheimer’s Association used
data from the results of a national telephone survey con-
ducted in 2009 for the NAC/AARP [184]. The NAC/
AARP survey asked respondents aged 18 years and older
whether they were providing unpaid care for a relative or
friend aged 18 years or older or had provided such care
during the past 12 months. Respondents who answered
affirmatively were then asked about the health problems of
the person for whom they provided care. In response, 26%
of caregivers said that (1) AD or another dementia was the
main problem of the person for whom they provided care
or (2) the person had AD or other mental confusion in
addition to their main problem. The 26% figure was
applied to the total number of caregivers nationally and in
each state, resulting in a total of 15,553,389 AD and
dementia caregivers.
A17The 2014 Alzheimer’s Association Women and Alz-
heimer’s Poll: This poll was conducted by telephone be-
tween January 9 and 29, 2014. Target respondents were
community-dwelling adults aged 18 years and older living
in the United States. Telephone numbers were chosen ran-
domly in separate samples of landline and cell phone ex-
changes from across the nation. Respondents were
contacted by either landline or cell phone.When a household
was contacted by landline, one adult from the household was
chosen at random to respond to survey questions. The survey
was designed to contain “oversamples” of Hispanics, Asian-
Americans, and households known to have an adult with AD.
Respondents included 1746 women and 1356 men (total of
3102 respondents); 2278 respondents identified themselves
as white non-Hispanic; 469 as of Hispanic Latino or Spanish
origin; 413 as black or African-American; 131 as Asian or
Asian-American; and 293 as another racial or ethnic group.
These cases were weighted to account for differential prob-
abilities of selection and overlap in the landline and cell
phone sampling frames. The sample was adjusted to match
census demographic benchmarks for gender, age, education,
race/ethnicity, region, and telephone service. The resulting
interviews (including the oversamples) comprise a
probability-based, nationally representative sample of US
adults. The margin of sampling error is approximately 62
percentage points at the 95% confidence interval. For sub-
groups, the margin of error will be higher.A18Number of hours of unpaid care: To calculate this
number, the Alzheimer’s Association used data from a
follow-up analysis of results from the 2009 NAC/AARP na-
tional telephone survey (data provided under contract by
Matthew Greenwald and Associates, November 11, 2009).
These data show that caregivers of people with AD and other
dementias provided an average of 21.9 hours a week of care,
or 1139 h/yr. The number of family and other unpaid care-
givers (15,533,389)A16 was multiplied by the average hours
of care per year, which total 17,689,423,440 hours of care.
A19Value of unpaid caregiving: To calculate this number,
the Alzheimer’s Association used the method of Amo et al.
[324]. This method uses the average of the federal minimum
hourly wage ($7.25 in 2013) and the mean hourly wage of
home health aides ($17.65 in July 2013) [325]. The
average is $12.45, which was multiplied by the number of
hours of unpaid care (17,689,423,440)A18 to derive the
total value of unpaid care ($220,233,321,824).
A20Higher health care costs of AD caregivers: This fig-
ure is based on a methodology originally developed by
Brent Fulton, Ph.D., for The Shriver Report: A Woman’s
Nation Takes on Alzheimer’s. A survey of 17,000 employ-
ees of a multinational firm based in the United States esti-
mated that caregivers’ health-care costs were 8% higher
than noncaregivers’ [326]. To determine the dollar
amount represented by that 8% figure nationally and in
each state, the 8% figure and the proportion of caregivers
from the 2009 BRFSSA16 were used to weight each
state’s caregiver and noncaregiver per capita personal
health care spending in 2009, inflated to 2013 dollars
[327]. The dollar amount difference between the
weighted per capita personal health care spending of
caregivers and noncaregivers in each state (reflecting the
8% higher costs for caregivers) produced the average
additional health-care costs for caregivers in each state. Na-
tionally, this translated into an average of $601. The
amount of the additional cost in each state, which varied
by state from a low of $443 in Utah to a high of $916 in
the District of Columbia, was multiplied by the total num-
ber of unpaid AD and dementia caregivers in that stateA16
to arrive at that state’s total additional health-care costs
of AD and other dementia caregivers as a result of being
a caregiver. The combined total for all states was
$9,331,554,412. Fulton concluded that this is “likely to
be a conservative estimate because caregiving for people
with Alzheimer’s is more stressful than caregiving for
most people who don’t have the disease” [300].
A21Lewin model on AD and dementia and costs: These
numbers come from a model created for the Alzheimer’s As-
sociation by The Lewin Group, modified to reflect the more
recent estimates and projections of the prevalence of AD
[114]. The model estimates total payments for community-
based health-care services using data from the Medicare
Current Beneficiary Survey (MCBS). The model was con-
structed based on 2004 MCBS data; those data have been re-
placed with the more recent 2008 MCBS data.A23 Nursing
Alzheimer’s Association / Alzheimer’s & Dementia 10 (2014) e47-e92e92facility care costs in the model are based on The Lewin
Group’s Long-Term Care Financing Model. More informa-
tion on the model, its long-term projections, and its method-
ology is available at www.alz.org/trajectory.
A22All cost estimates were inflated to year 2013 dollars us-
ing the Consumer Price Index (CPI): All cost estimates were
inflated using the seasonally adjusted average prices for med-
ical care services from all urban consumers. The relevant item
within medical care services was used for each cost element.
For example, themedical care itemwithin the CPI was used to
inflate total health-care payments; the hospital services item
within the CPI was used to inflate hospital payments; and
the nursing home and adult day services item within the
CPI was used to inflate nursing home payments.
A23MCBS report: These data come from an analysis of
findings from the 2008 MCBS. The analysis was conducted
for the Alzheimer’s Association by Julie Bynum, M.D.,
M.P.H., Dartmouth Institute for Health Policy and Clinical
Care, Center for Health Policy Research (155). The
MCBS, a continuous survey of a nationally representative
sample of about 16,000 Medicare beneficiaries, is linked
to Medicare part B claims. The survey is supported by the
US Centers for Medicare and Medicaid Services. For
community-dwelling survey participants, MCBS interviews
are conducted in person three times a year with the Medicare
beneficiary or a proxy respondent if the beneficiary is not
able to respond. For survey participants who are living in a
nursing home or another residential care facility such as an
assisted living residence, a retirement home, or a long-
term care unit in a hospital or mental health facility,
MCBS interviews are conducted with a nurse who is familiar
with survey participants and their medical record. Data from
the MCBS analysis that are included in 2013 Alzheimer’s
Disease Facts and Figures pertain only to Medicare benefi-
ciaries aged 65 years and older. For this MCBS analysis,
people with dementia are defined as:
 Community-dwelling survey participants who answered
yes to the MCBS question, “Has a doctor ever told you
that you had Alzheimer’s disease or dementia?” Proxy
responses to this question were accepted.
 Survey participants who were living in a nursing home
or other residential care facility and had a diagnosis of
AD or dementia in their medical record.
 Survey participants who had at least one Medicare
claim with a diagnostic code for AD and other demen-
tias in 2008: The claim could be for anyMedicare serv-
ice, including hospital, skilled nursing facility,
outpatient medical care, home health care, hospice or
physician, or other health-care provider visit. The diag-
nostic codes used to identify survey participants with
AD and other dementias are 331.0, 331.1, 331.11,
331.19, 331.2, 331.7, 331.82, 290.0, 290.1, 290.10,
290.11, 290.12, 290.13, 290.20, 290.21, 290.3,
290.40, 290.41, 290.42, 290.43, 291.2, 294.0, 294.1,
294.10, and 294.11.Costs from the MCBS analysis are based on responses
from 2008 and reported in 2013 dollars.
A24Differences in estimated costs reported by Hurd et al.:
Hurd et al. [173] estimated per-person costs using data from
participants in ADAMS, a cohort in which all individuals
underwent diagnostic assessments for dementia. 2014 Alz-
heimer’s Disease Facts and Figures estimated per-person costs
using data from the Medicare Current Beneficiary Survey
(MCBS). One reason that the per-person costs estimated by
Hurd et al. are lower than those reported in Facts and
Figures is that ADAMS, with its diagnostic evaluations of
everyone in the study, is more likely thanMCBS to have iden-
tified individualswith less severe or undiagnosedAlzheimer’s.
By contrast, the individuals with Alzheimer’s registered by
MCBS are likely to be those with more severe, and therefore
more costly, illness. A second reason is that Hurd et al.’s esti-
mated costs reflect an effort to isolate the incremental costs as-
sociated with Alzheimer’s disease and other dementias (those
costs attributed only to dementia), while the per-person costs
in Facts and Figures incorporate all costs of caring for people
with the disease (regardless ofwhether the expenditurewas re-
lated to dementia or a coexisting condition).
A25YouGov survey: Sample targets for this August 2013
survey by YouGov were set based on demographic character-
istics of adults aged 60 years or older from the 2010American
Community Survey. After proximity matching, the matched
set of survey respondents were then weighted to known char-
acteristics in the United States using propensity score weight-
ing. The final weights were then poststratified by
demographic characteristics to be representative of the gen-
eral population aged 60 years or older. The YouGov survey
was conducted with financial support from the Alzheimer’s
Association; data analysis was supported by the CDC.
A26Number of respondents who identified themselves as
caregivers for someone with AD or dementia: The 2014 Alz-
heimer’s Association Women and Alzheimer’s PollA17 in-
cluded 205 caregivers of people with AD or dementia. This
was supplemented with 310 interviews from a listed sample
of caregivers to people with AD. For this survey, a caregiver
was defined as an adult older than age 18 years who, in the
past 12 months, has provided unpaid care to a relative or
friend aged 50 years or older with AD or dementia. Further-
more, caregivers had to report that they provided the majority
of care or equally shared caregiving responsibilities with an-
other person. Unfortunately, there are no official demographic
benchmarks for the AD caregiver population. As a substitute,
benchmark estimates for this population were derived from
the characteristics of the caregivers reached in the landline
and cell phone samples, which are probability based and na-
tionally representative. The weight for the caregiver sample
balances all caregiver cases to the weighted estimates for gen-
der and race/ethnicity derived from the landline and cell
phone caregivers. This weighting adjusted for the fact that
the caregivers reached through the list sample were somewhat
more likely to be female and white than those reached in the
probability-based component of the study.
